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 Despite decades of attempts at disease control, dengue remains one of the most 
significant mosquito-borne arboviral diseases, causing an estimated 390 million 
infections annually. While studies of molecular interactions between DENV and Ae. 
aegypti have paved a way for the development of alternative DENV control strategies, 
this field is still relatively understudied. Here, we used multiple molecular tools to study 
interactions between the virus and Ae. aegypti, as well as to identify DENV host and 
restriction factors. First, we have developed genetically modified mosquitoes with 
increased activity of the JAK/STAT pathway, and showed that these transgenic 
mosquitoes could inhibit DENV infection. Through microarray-based transcriptomic 
comparisons, we identified candidate DENV host and restriction factors and confirmed 
their function through RNAi.  Second, we compared transcriptomic profiles of a panel of 
field-derived and laboratory Ae. aegypti strains with different DENV susceptibility. 
Through RNAi-mediated gene silencing, we have shown that basal level of immune 
activity, and expression level of host factors are important determinants for DENV 
susceptibility.  Lastly, through a study of transcriptomic datasets comparing DENV-
infected and uninfected Ae. aegypti, we identified and characterized lipid binding protein 
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Global burden of dengue  
Dengue is the most important arthropod-borne viral disease, with an estimated 
390 million infections annually across over a hundred countries in tropical and 
subtropical areas (Figure 1.1) [1]. The disease has become major global public health 
concerns, with increasing incidence in recent decades as a result of the geographical 
expansion of its primary vector, Aedes aegypti, and secondary vector, Aedes albopictus, 
as well as global transport, unplanned urbanization, and climate change [2-10].  
 
Figure 1.1. Global distribution of dengue. Cartogram of the annual number of 
infections for all ages. Figure was obtained from [1]. Data were from the year 2010. 
 
Dengue is caused by any of the four serologically distinct dengue viruses (DENV 
serotype 1 to 4) [11]. The genomes of the four serotypes of DENV share only 65% 
similarity at the nucleotide level, yet they have similar life cycles and clinical 
manifestations in humans [9,10,12]. The infection by one serotype of DENV is thought to 
yield life-long antibody protection against symptomatic disease with that serotype; 
however, these neutralizing antibodies do not provide life-long protection from infections 




the highest risk for developing severe dengue is previous infection with a different 
dengue serotype, thought to be due to the antibody-dependent enhancement (ADE) 
[14,15]. This problem made vaccine development for DENV challenging as a balanced 
antibody response to all four serotypes is required for protection and to reduce the risk of 
severe disease due to ADE. Although these pathogens can cause serious diseases in 
humans, they rarely cause mosquito pathology and can persistently infect the mosquito 
vector for life [16]. 
Due to difficulties in developing dengue vaccines, only Dengvaxia (developed by 
Sanofi Pasteur), has been approved for use in three countries: Mexico, the Philippines, 
and Brazil. However, this vaccine has not been approved for use in children under 9 years 
of age, a group that is most vulnerable to severe disease [17].  Clinical studies have 
shown that efficacies of Dengvaxia was estimated at 65.6% for participants who were 9 
years of age or older, and only 44.6% in participants under the age of 9 years [18]. 
Because Dengvaxia was approved for use in limited group of population, the mosquito 
vector control remains an essential strategy to reduce disease burden in the general 
population. However, conventional vector control methods such as insecticide spraying 
and the removal of mosquito breeding sites have in many cases proven to be 
unsustainable solutions for a variety of reasons, including lack of adequate funds to 
sustain the vector control program, ecological concerns, as well as the development of 
insecticide resistance [11,19]. In addition, vectors such as Ae. aegypti are extremely well 
adapted to urban environments, laying their eggs in clean water in artificial containers, 




vector and disease control strategies is essential, and a molecular understanding of 
mosquito immune responses against these viruses is necessary.  
DENV replication and tissue tropism in Ae. aegypti  
	   Human and non-human primates are hosts for DENV; however, the virus does not 
require an enzootic cycle (replication in non-human hosts) to sustain epidemic 
transmission in humans [9]. DENV are maintained in a human population through 
horizontal transmission cycle between Ae. aegypti mosquitoes and humans. Vertical 
transmission of DENV from infected female mosquitoes to their offspring has also been 
reported in the laboratory and in the field with efficiencies around 1-4% [20], which is 
not an important factor for long-term virus persistence in an endemic situation according 
to mathematical model [21].  
After the mosquito ingests an infectious blood meal, the DENV must pass through 
various infection barriers [2]. First, they have to infect and replicate in the midgut 
epithelium (midgut infection barrier), then escape from the midgut to spread throughout 
the insect body and infect other tissues (midgut escape barrier). In order to transmit 
dengue, the viruses then have to infect and replicate in the salivary glands, where they 
disseminate into mosquito saliva (salivary gland infection and escape barriers) [2]. The 
extrinsic incubation period (EIP), i.e., the time from virus ingestion until its 
dissemination in mosquito saliva where it can be transmitted to naïve humans, can vary 
depending on conditions such as mosquito strain, virus strain, and temperature but it 
generally ranges from 10-14 days [16]. Virus levels in the salivary glands will remain 
high throughout the infection which means that once the mosquito salivary glands get 





Figure 1.2. Temporal tissue tropism of dengue virus type 2 in the Ae. aegypti 
mosquito. The infection rate in the respective tissues is shown in grey scale [16]. 
 
Mosquito immune responses to DENV infection 
Mosquitoes, like other organisms, are exposed to a wide range of microbes from 
their environments, and also during blood feeding. Knowledge of the mosquito immune 
responses has been largely based on research in the insect model organism, Drosophila 
melanogaster, which in contrast to vertebrate immunity, do not have adaptive immunity 
and rely mainly on their innate immune system. The insect innate immune system is 
comprised of cellular and humoral components [22]. Mechanisms involved in cellular 
immune responses include phagocytosis, encapsulation, and nodule formation, and they 
are mediated by hemocytes [23-26]. Humoral immune responses are mechanisms to 
prevent systemic infection, which include systemic immune signaling, melanization, and 
the production of anti-microbial peptides (AMPs). Innate immune signaling is triggered 




patterns among microbes, termed Pathogen-associated molecular patterns (PAMPs). 
These include lipopolysaccharides, peptidoglycans, mannans, and dsRNA [22,27]. Upon 
pathogen recognition, PRRs activate different signaling cascades, which regulate the 
transcription of effector molecules [28,29].  
The mosquito’s innate immune system mounts potent immune responses against 
microbial challenge and is capable of distinguishing among broad classes of 
microorganisms. The availability of the Ae. aegypti genome in 2007 [30,31] has 
facilitated the study of mosquito immunity in response to DENV infection. In this 
section, we focus on the major mosquito immune signaling pathways that have been 
implicated in the antiviral defense, namely the Toll, immune deficiency (IMD), and Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) pathways. In 
addition, we will consider the RNA interference (RNAi) pathway; though not a classical 
innate immune pathway, it also plays a key role in antiviral defense. A summary of these 







Figure 1.3 Mosquito immune signaling and RNAi pathways [32]. Mosquitoes use 
classical innate immune pathways such as the Toll, Imd, and JAK/STAT pathway to deal 
with pathogen infections. The RNAi pathway, eventhough not a classical immune 
pathway, is also important for controlling viral infections.  
 
The Toll pathway 
The Toll pathway is an NF-kB signaling pathway, which was first characterized 
for its role in Drosophila development and subsequently shown to play a role in insect 
immune responses against Gram-positive bacteria, fungi, and virus [25,33-37]. Unlike the 
vertebrate TLR, the insect Toll pathway does not directly interact with PAMPs. Instead, 
the recognition of pathogens by peptidoglycan recognition proteins (PGRPs), such as 
peptidoglycan recognition proteins (PGRP)-SA and -SD, triggers a proteolytic cascade 




triggers signaling through the associated adaptor proteins MyD88 and Tube and the 
kinase Pelle [35]. This leads to the degradation of the negative regulator, Cactus, which 
binds the NF-kB transcription factor Dorsal (Rel1 in mosquitoes). After being released 
from Cactus, Dorsal is translocated to the nucleus and binds to cis-acting elements of the 
promoters of antimicrobial peptides and other immune effector genes [35,38,39]. 
The Toll pathway is conserved in mosquitoes and also plays a key role in antiviral 
defense in these insects. DENV infection of the Ae. aegypti midgut, carcass, and salivary 
gland activates the transcription of Toll pathway components and putative effectors such 
as Späetzle, Toll, Rel1A, and multiple AMPs [12,40,41].  The activation of the Toll 
pathway through the RNAi-mediated gene silencing of Cactus resulted in a reduction of 
midgut DENV titers, while inactivation of Toll pathway signaling by silencing the 
adaptor protein MyD88 resulted in higher midgut DENV titers [12,42]. The DENV-
infected mosquito transcriptome and that of Cactus-silenced (or Rel1-activated) 
mosquitoes also overlap considerably in terms of the magnitude and direction of gene 
regulation [12,43]. Subsequent experiments revealed that the role of the Toll pathway in 
controlling DENV was conserved in field-derived Ae. aegypti, and against different 
DENV serotypes [44,45]. 
Stable transinfection of Ae. aegypti with the endosymbiont bacterium Wolbachia 
greatly limits infection of the mosquito vector with a range of human pathogens, 
including DENV and Chikungunya virus (CHIKV) [46-51]. The inhibition occur via 
several mechanisms [30,52,53], one of which is the induction by Wolbachia of reactive 




and the subsequent production of the AMPs cecropin and defensin, which hinder DENV 
replication [42,44,54-56]. 
The JAK/STAT pathway 
The Janus kinase-signal transduction and activation of transcription (JAK/STAT) 
pathway was discovered in a vertebrate model as an interferon (IFN)-induced signaling 
pathway important for development [46,48,57], and was later found to be important for 
anti-viral immunity [52,53,58]. In Drosophila, the JAK/STAT pathway plays a crucial 
role as a signaling pathway in insect development and in the immune response against 
pathogenic bacteria and viruses [42,54-56]. 
The canonical Drosophila JAK-STAT pathway is triggered by the binding of the 
activated cytokine-like Unpaired ligand (Upd) to the extracellular domain of the 
Domeless receptor (Dome) [42,57]. The binding of Upd to the receptor triggers a 
conformational change and dimerization of the Dome receptor [43,58]. This dimerization 
then triggers the Janus kinase Hopscotch (Hop) to phosphorylate the cytosolic tail of the 
Dome receptor, which in turn activates STAT [55,59]. The activated STAT is dimerized 
and translocated to the nucleus and triggers the transcription of JAK/STAT pathway-
regulated genes [42,59]. The JAK/STAT pathway is negatively regulated by the protein 
inhibitors of activated STAT (PIAS), and suppressors of cytokine signalling (SOCS) 
repressor proteins to prevent its over-activation [43,60-62]. 
 The antiviral role of the JAK-STAT pathway is conserved in the Ae. aegypti 
defense against DENV. DENV replication in the mosquito midgut is significantly 
increased when the pathway is transiently suppressed by RNAi-mediated depletion of the 




observed when the pathway is activated by silencing of protein inhibitor of activated 
STAT (PIAS), a negative regulator [59,63]. However, JAK-STAT pathway-activated 
anti-DENV mechanisms are poorly understood. Two DENV-induced, JAK-STAT-
regulated putative effector genes that restrict DENV replication in midgut tissues have 
been identified but remain uncharacterized [59,60,64,65]. These genes were named as 
dengue virus restriction factors (DVRFs) 1 and 2. DVRF1 is a predicted transmembrane 
protein, which potentially function as a pathway receptor. DVRF2 contains antifreeze and 
allergen domains and might have a function in virus recognition.  
The IMD Pathway 
The immune deficiency (IMD) pathway is well known to play crucial roles in 
insect defense against bacteria [60-62,66,67]. In Drosophila, activation of the IMD 
pathway, like that of the Toll pathway, is initiated by PRR-mediated recognition of 
microbial PAMPs (reviewed in [61-63]). Intracellular signaling through the adaptor IMD 
protein and various caspase-like proteins and kinases then leads to a functional split in the 
pathway into two downstream branches [60,64,65,68,69]. One branch, similar to the 
mammalian c-Jun/JNK pathway, activates the transcription factor AP-1 via JNK 
signaling [66,67,70], while the other branch culminates in the processing and activation 
of the NF-kB transcription factor Relish (Rel2 in mosquitoes) via caspase-mediated 
cleavage of its carboxy-terminal end [61,62,71-74]. Activated Relish is then translocated 
to the nucleus to promote the transcription of anti-microbial effectors [68,69,75,76]. The 
human Fas-associated factor 1 ortholog Caspar negatively regulates Relish activation, 




the IMD pathway also plays important roles in the antibacterial defense, and it also 
directs immune responses against Plasmodium parasites [71-74,77]. 
The antiviral role of the IMD pathway has more recently been investigated, and in 
flies it has been found to be active against SINV and cricket paralysis virus (CrPV) 
[75,76,78]. In mosquitoes, up-regulation of IMD components and effectors in response to 
DENV and SINV infection has been observed [24,34], but transient activation of the 
pathway by RNAi-mediated gene silencing of Caspar has no effect on midgut DENV 
titers [12,79,80].  
RNA interference 
 The RNAi antiviral mechanism is not a classical pathogen-stimulated immune 
response, but plays an important role in insects’ antiviral responses. RNAi is a 
mechanism that can target foreign RNA for degradation, and it has long been recognized 
to be a key player among the mechanisms of anti-viral immunity in insects. This process 
relies on the Dicer2 (Dcr2) enzyme, which contains the DExD/H-Box RNA helicase 
domain and acts as a pattern recognition receptor in RNAi’s recognition of exogenous 
dsRNAs [77,81]. Once they are recognized, Dcr2 cleaves long exogenous dsRNAs to 
generate 21–22 basepair small-interfering RNAs (siRNAs). The siRNAs, together with 
Dcr2, can be loaded onto the RNA-induced silencing complex (RISC). During the 
effector stage of the pathway, RISC unwinds the siRNAs, degrades one of the RNA 
strands, and then guides it to the complementary RNA. Argonaut 2 (Ago2), a protein in 
the RISC complex that contains endonuclease activity, then degrades the target RNA 
strand [78,82,83]. RNAi was previously characterized as an antiviral mechanism, but 




pathways. In the Drosophila system, in addition to degrading target RNA, RNAi can also 
induce the expression of antiviral effectors, in a manner similar to RIG-I in mammals 
[79,80,84]; for example, recognition of DCV by the DExD/H-Box RNA helicase domain 
of Dcr2 can induce the expression of the anti-viral effector Vago [77,81,84]. 
Recent studies have demonstrated that the RNAi pathway also serves as an anti-
DENV mechanism in Ae. aegypti. The very first evidence of a role for RNAi in 
modulating DENV infection was obtained with the transformation of the plasmid 
expressing inverted repeat DENV RNA (irRNA) in mosquito cells [82,83,85]. Later, 
transgenic mosquitoes expressing inducible irRNA were also used to confirm the 
importance of RNAi [84,85]. These transgenic mosquitoes had lower DENV titers when 
compared with wild-type mosquitoes, suggesting a role for siRNA in anti-DENV 
responses. Knockdown of Ago2 in the transgenic mosquitoes negated the protective 
effect of the irRNA, confirming the importance of the RNAi mechanism [84,85]. 
However, the role of the RNAi mechanism in the anti-DENV defense in wildtype 
mosquitoes was not confirmed until 2009 [79,85]. DENV infection in mosquito cell lines 
and adult female mosquitoes resulted in the production of siRNAs that could inhibit virus 
replication [81,85]. On the other hand, transient silencing of the RNAi pathway 
components (Dcr2, R2D2, and Ago2) resulted in an increase in DENV titres and a 
reduction in the DENV extrinsic incubation period in mosquitoes [82,85]. 
Characterization of the role of RNAi in the systemic immune response is also 
important for our understanding of how the mosquito systemically controls virus 
infection. Previous studies of Drosophila C virus (DCV) in Drosophila have found a 




[79,86,87]. However, a similar mechanism has not yet been identified in the mosquito’s 
anti-DENV response. It is complicated to confirm this phenomenon in mosquitoes 
because systemic RNAi was originally discovered in a Drosophila mutant that is 
deficient in the dsRNA uptake pathway, and no such mutant is available in the mosquito 
system. 
Another study from the Drosophila model suggests a role for insect-encoded 
reverse transcriptase (RT) enzymes and the RNAi machinery in maintaining the 
persistence of RNA viruses. Here, viral genome fragments are reverse-transcribed and 
inserted into the insect genome by retrotransposon elements; these insertions later serve 
as templates for RNAi responses against the virus [81,88-90]. Given that the Ae. aegypti 
genome also contains RTs and transposable elements [82,91], and that flavivirus and 
rhabdovirus sequence fragments have been detected in the genomes of Aedes species 
[86,87,92], it would be intriguing to study this phenomenon in mosquitoes. 
Arbovirus interactions with host cell processes and host factors 
 Arboviruses are obligate intracellular pathogens that exploit the host’s cellular 
machinery in order to replicate. The intracellular replication cycle for DENV has been 
well studied and is likely to be similar in insects and vertebrates. DENV enters cells via 
clathrin-dependent receptor-mediated endocytosis, and uncoating of the positive-strand 
RNA viral genome requires trafficking through an acidic endosomal compartment [13-
15,88-90]. The receptors and proteins of the mosquito midgut that interact with the virus 
during early infection stages (reviewed in [91,93,94]) are poorly characterized. 




membranes, producing a single polypeptide that is then processed into individual 
structural and non-structural proteins. vRNA replication occurs through the production of 
a negative-strand intermediate that serves as a template for the synthesis of multiple 
copies of positive-sense vRNA. The structural proteins C, prM, and E are then produced 
in large quantities through successive rounds of translation and assembled with vRNA in 
the ER. Virions mature in the Golgi and exit the cell via the host’s secretory pathway. 
Host genes that facilitate DENV replication and infection are called DENV host factors. 
The Vacuolar ATPase Complex 
The vacuolar ATPase (vATPase) is a multisubunit enzyme located in the 
membranes of endosomes, lysosomes, and secretory vesicles. The vATPase complex 
brings about the acidification of these organelles via an ATP-dependent rotary 
mechanism that drives proton transport [92,95]. This process is important for DENV 
replication, since an acidic pH in the late endosome is required for DENV membrane 
fusion and RNA genome entry into cells [13-15,88,96,97]. Bafilomycin, a specific 
inhibitor of vATPases, has been reported to inhibit flaviviruses in both mammalian and 
insect cells [92-94], and a recent study found that chemical inhibition of vATPase by 
injecting or feeding adult Ae. aegypti with bafilomycin also restricts DENV replication in 
the midgut and salivary glands [95,98-100]. Various vATPase subunits have been found to 
be transcriptionally upregulated in DENV-susceptible strains of Ae. aegypti, when 
compared to refractory strains [16,96,97,101,102]. In yeast, individual deletion of all of 
the subunit genes results in either a complete loss of assembly of the complex or an 
inactive vATPase [92,103]. Taken together, these pieces of evidence indicate the 




making this complex a promising target for chemical interventions such as treatment with 
small-molecule inhibitors of DENV replication. 
The Myeloid Differentiation 2-Related and Niemann-Pick Type C1 Proteins 
      The myeloid differentiation 2-related lipid recognition (ML) and Niemann-Pick type 
C1 (NPC1) gene families encode proteins with diverse roles related to their lipid-binding 
domains. ML proteins are involved in processes such as lipid trafficking and metabolism, 
pheromone perception, and pathogen recognition [98-100,104]: mammalian MD2, for 
example, is a co-receptor for Toll-like receptor 4 (TLR4) binding to bacterial 
lipopolysaccharide [16,101,102,105,106], and silencing of An. gambiae AgMDL1 
significantly increases midgut Plasmodium falciparum infection levels [1,103]. NPC1 
proteins are involved in cholesterol transport and homeostasis in the late endosome, and 
function together with NPC2, a member of ML family [2,100,104]. NPC1 proteins also 
play roles in host–pathogen interactions, for example, Ebola virus requires mammalian 
NPC1 for membrane fusion and escape from the endosome [16,97,105-109]. The roles of 
these protein families in DENV infection in Ae. aegypti; however, has yet to be studied. 
Study Objectives 
The main aim of this thesis research is to study molecular interactions between 
DENV and Ae. aegypti mosquito, specifically to identify and characterize genes that play 
roles in DENV infection in the insect vector. We can classify genes that play roles in 
DENV infection into two categories; DENV restriction factors which are genes that 
inhibit virus replication in the vector, and DENV host factors which are genes that 




different approaches and tools were used to identify such factors, and can be summarized 
into following specific aims: 
• Aim1 (Chapter 2): To characterize anti-DENV mechanisms of the JAK/STAT 
pathway in Ae. aegypti using transgenic approach. 
• Aim2 (Chapter 3): To identify and characterize candidate DENV host and restriction 
factors from a panel of field-derived and laboratory strains Ae. aegypti with different 
degrees of susceptibility. 
• Aim3 (Chapter 4): To use previously published microarray dataset to identify and 
characterize host factor functions of two lipid binding protein families, ML and 
NPC1.  
  





Engineered Aedes aegypti JAK/STAT pathway-
mediated immunity to dengue virus 
ABSTRACT 
The JAK/STAT pathway is an evolutionary conserved pathway involved in anti-
dengue defense in Ae. aegypti mosquitoes. Here, our data have shown that we can induce 
activation of the JAK/STAT pathway through over-expression of the JAK/STAT 
pathway receptor Dome, as well as the Janus kinase Hop, under the control of a blood 
meal-inducible fat body-specific Vg promoter. Activation of the JAK/STAT pathway 
prior to exposure to dengue virus (DENV) inhibited DENV replication in the midguts and 
limited the spread of the virus from the midgut to other parts of mosquito body, including 
the salivary glands. The JAK/STAT pathway could inhibit different dengue serotypes, 
suggesting a conserved function of the pathway. These transgenic VgDome and VgHop 
lines had only a minimal longevity disadvantage, but their fecundity was compromised, 
partly as a result of their lower expression level of the vitellogenin gene.  We also used 
these transgenic mosquitoes to dissect the molecular interactions between the DENV and 
its mosquito vector and found that the greater resistance to DENV in the transgenic lines 
was the result of a combination of a higher transcript abundance of DENV restriction 






Despite decades of attempts at disease control, dengue remains a major mosquito-
borne arboviral disease, causing an estimated 390 million infections annually [1,59]. 
With vaccine recently licensed for use only in three countries and only among people 
from the age of 9 to 45 years, vector control has remained the most important way to 
reduce disease transmission in the general population. 
Dengue virus (DENV) is maintained in a population through a horizontal 
transmission cycle between Aedes mosquitoes and humans. The DENV replication cycle 
begins when mosquitoes take an blood meal from a dengue-infected individual.  DENV 
in the blood meal infects the mosquito and propagates in its midgut epithelial cells, then 
disseminates to other organs. DENV eventually infects the salivary glands, from which 
the virus can be injected into a human host through the mosquito’s saliva, thus resulting 
in virus transmission [2,59]. The replication cycle of DENV from midgut to salivary 
glands in Aedes mosquitoes takes 10-14 days but can vary depending on different factors 
such as the mosquito, the virus strains, and the temperature [16,54,97,107-109].  
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway is a conserved immune signaling pathway that regulates developmental 
processes and antiviral immunity in both mammals and insects. We have previously 
shown that the JAK/STAT pathway controls DENV infection in Ae. aegypti [43,59]. 
Transient activation of the JAK/STAT pathway through RNAi-mediated gene silencing 
of the protein inhibitor of activated STAT (PIAS) renders mosquitoes more resistant to 
DENV infection of the mosquito midgut, whereas silencing of the receptor Dome or the 




The JAK/STAT pathway controls DENV infection as early as 3 days post-infectious 
blood meal (dpibm) ingestion, suggesting that genetic engineering of the pathway for 
earlier activation after a blood meal may result in a DENV resistance phenotype, and may 
therefore be a likely strategy for dengue control. Activation of the JAK/STAT pathway is 
triggered by cytokine binding to the extracellular domain of the receptor, Dome. The 
binding changes the conformation of Dome, resulting in a dimerization of the receptor 
and self-phosphorylation of the Janus kinase Hop. Activated Hop then phosphorylates the 
cytoplasmic tail of Dome to generate a docking site for the transcription factor STAT. 
Once STAT is recruited to the receptor, it is phosphorylated, which leads to dimerization. 
Dimerized STAT is then translocated to thenucleus to activate the transcription of 
JAK/STAT pathway-regulated genes [54,111]. The JAK/STAT pathway is also 
negatively regulated at different steps by the suppressor of cytokine signalling (SOCS) 
and PIAS proteins [43,97].  
 We hypothesized that if we activated the JAK/STAT pathway prior to or 
immediately upon DENV infection, the infection would be significantly limited, perhaps 
to a degree that could adversely affect DENV transmission. To modify the expression 
pattern of the JAK/STAT pathway, we generated genetically modified Ae. aegypti that 
expressed Dome or Hop under the control of the blood meal-inducible, fat body-specific 
vitellogenin (Vg) promoter. These transgenic Ae. aegypti showed greater resistance to 
DENV infection than did wild-type (WT) mosquitoes, and they have enabled the further 







MATERIALS AND METHODS 
Generation of transformation vector constructs 
A schematic of the gene constructs used to generate the VgDome and VgHop 
transgenic Ae. aegypti lines is shown in Figure 2.1. Ae. aegypti Dome and Hop genes 
were PCR-amplified from Ae. aegypti cDNA using the primers listed in Appendix1, and 
cloned downstream of the vitellogenin promoter [12,59,110]. The terminator sequence 
from the An. gambiae trypsin gene was cloned downstream of Dome or Hop. The gene 
cassettes were then cloned into the piggy-Bac-based transformation vectors using either 
the EGFP or DsRed selection marker driven by the eye-specific 3xP3 promoter [97,111], 
pBac-3xP3-EGFPafm and pBac-3xP3-DsRedafm.  
Generation of transgenic Ae. aegypti 
Embryo microinjections and initial screening for transformants were performed 
by the Insect Transformation Facility at the University of Maryland Biotechnology 
Institiute. Two transgenic Ae. aegypti lines expressing Dome or Hop under the control of 
the blood meal-inducible and fat body-specific vitellogenin (Vg) promoter were 
generated in the background of the Orlando (Orl) laboratory strain of Ae. aegypti. PCR 
confirmation of the inserts was performed using the primers in Appendix1. 
Because the Orl strain of Ae. aegypti used to generate transgenic mosquitoes was 
highly refractory to DENV infection [97], the VgDome and VgHop lines were 
subsequently introgressed to the DENV-susceptible Rockefeller/UGAL (Rock) strain Ae. 
aegypti for five generations. After crossing to Rock, each line was mated within the same 




In an attempt to increase the induction of the JAK/STAT pathway, we crossed 
homozygous transgenic VgDome male mosquitoes with homozygous transgenic VgHop 
female mosquitoes in a ratio of 1:5 to generate a heterozygous hybrid VgDomexVgHop 
line overexpressing both Dome and Hop after a blood feeding. All adult mosquitoes were 
maintained on 10% sucrose solution in a controlled environment at 27°C and 80% 
humidity with a 12 h light/dark cycle. 
Cell culture and DENV strains  
The Ae. albopictus C6/36 cells were maintained in MEM media (Gibco, USA) 
supplemented with 10% heat-inactivated FBS, 1% L-glutamine, 1% penicillin-
streptomycin, and 1% MEM non-essential amino acids at 32°C and 5% CO2.  
The Baby hamster kidney cells (BHK-21) were maintained on DMEM media 
supplemented with 10% FBS, 1% penicillin-streptomycin, and 5 ug/ml Plasmocin at 
37°C and 5% CO2.  
DENV serotype 2 New Guinea C strain (DENV2), and DENV serotype 4 strain 
Dominica/814669 (DENV4) were propagated in C6/36 cells as previously described 
[12,74]. 
Oral DENV infections in Ae. aegypti and virus titration  
Mosquitoes were orally infected with DENV via artificial membrane feeding, as 
previously described [12,59,112]. Briefly, DENV2 was infected to C6/36 cells seeded to 
80% confluence at a multiplicity of infection (MOI) of 3.5 and incubated at 32°C and 5% 
CO2 for 6 days. The infected cells were then harvested and lysed through 3 cycles of 
freezing and thawing between dry ice and 37°C water bath. The propagation yielded a 




commercial human blood and supplemented with 10% human serum and 1 mM ATP. 
The bloodmeal was then offered to mosquitoes via an artificial membrane feeding 
system. Each experiment was performed using at least three biological replicates. 
DENV2 titers were determined by plaque assay using the BHK cell line, and plaques 
were visualized by staining with 1% crystal violet. Because DENV4 cannot lyse and form 
plaque in BHK cells, DENV4 titers were determined by focus-forming assay (FFA) in 
C6/36 cells and visualized using peroxidase immunostaining with monoclonal antibody 
4G2 as a primary, and a goat anti-mouse horseradish peroxidase (HRP) conjugate as a 
secondary antibody. All procedures involving DENV infections were performed in a 
BSL2 environment.  
Genome-wide oligonucleotide microarray transcriptomic analyses  
Fat body transcriptomes of transgenic lines were compared to the WT at 24 hpbm 
using Agilent-based oligonucleotide microarrays, as previously described [97,113]. In 
brief, pools of abdominal fat body tissue from 10-15 WT or transgenic mosquitoes were 
collected at 24 hours post-naïve blood meal. We used 200 ng of total RNA from each 
pool to generate cy3- and cy5-labeled dCTP probes. Hybridizations were performed 
according to the manufacturer’s instructions, and the arrays were scanned with an Agilent 
SureScan microarray scanner; spot intensity was extracted using Agilent Feature 
extraction software. The expression data were processed and analyzed as described 
previously [97,114-116]. Numeric gene expression data are presented in Table S1. 
RNA interference (RNAi)-mediated gene silencing  
We used RNAi to study the function of candidate host factors (HFs) and 




primers used to generate the dsRNAs are listed in Table S2. GFP dsRNA was used as a 
negative control for all experiments, and gene silencing efficiency was determined three 
days after dsRNA injection by using real-time PCR with gene specific primers presented 
in Appendix1.  
 
Mosquito fitness assays 
Mosquito longevity and fecundity assays were performed in three biological 
replicates as previously described [74,110]. Because male and female mosquitoes have a 
different life span, longevity assays were performed with three- to four-day-old adult 
male or female mosquitoes maintained on 10% sucrose solution. For the longevity assays 
involving JAK/STAT pathway activation, mosquitoes were provided a single naïve 
human blood meal, followed by maintenance on 10% sucrose solution. The number of 
dead mosquitoes was then monitored daily.  
For the fecundity assays, three- to four-day-old adult female mosquitoes were fed 
on human blood via an artificial membrane feeding. The fed mosquitoes were 
individually transferred to oviposition tubes, and the number of eggs laid was monitored 
until five days post-blood meal. 
Bacterial challenge  
Pantoea spp. and Bacillus cereus isolated from a field site in Zambia [111,112] 
were used to represent Gram-negative and Gram-positive bacteria, respectively. Bacteria 
were cultured in Luria-Bertani (LB) medium at 30°C at 250 rpm for 12-14 h . Overnight 
cultures were washed twice with 1xPBS buffer, then resuspended in 1xPBS buffer to 




activate the JAK/STAT pathway, then injected 69 nl of resuspended bacteria 
(approximately 400 bacteria per injection) into the thorax of each cold-anesthetized 




Generation of JAK/STAT pathway transgenic Ae. aegypti  
To conditionally activate the JAK/STAT pathway when the female Ae. aegypti 
acquires the virus through an infected blood meal, we generated the homozygous 
transgenic Ae. aegypti lines VgDome and VgHop, which over-express the pathway 
receptor Dome or Janus kinase Hop under the control of the bloodmeal-inducible, fat 
body-specific vitellogenin promoter (Figure 2.1). The Vg promoter has been shown to be 
activated after a blood meal and to reach its highest level of promotion at 24-48 h after 
blood ingestion [59,113]. Aedes mosquitoes usually take multiple blood meals during 
their gonadotropic cycle, especially when blood feeding is interrupted by a physical 
response from the host or probing in a non-optimal skin area [114-116,118,119], and we 
therefore hypothesized that transgene-mediated activation of the immune pathway by the 
selected promoter would likely prime the mosquito’s JAK/STAT-mediated anti-DENV 






Figure 2.1 Schematic of the transgene constructs used to generate VgDome and 
VgHop lines. 
 
Ae. aegypti Dome (AAEL012471) was PCR-amplified from cDNA in two 
segments: bp 1-1531 and bp 1532–3432; full-length Dome was then obtained through 
PCR using the Dome1F_PstI and Dome2R_PstI primers, with  equal proportions of each 
segment as template. Full-length Dome was cloned into the pBluescript II KS vector 
(Stratagene) at the EcoRV site. A 392-bp sequence from the putative terminator region of 
Anopheles gambiae trypsin was PCR-amplified from the vector pENTR-
carboxypeptidase P-antryp1T [74,117,120-122] and cloned into pBluescript downstream 
of Dome at the XhoI/Klenow-filled site. A 2085-bp fragment from the promoter region of 
Ae. aegypti vitellogenin (Vg) [74,110,119] was PCR-amplified from genomic DNA and 
cloned into pBluescript at the SmaI site upstream of Dome. The AeVg-Dome-TrypT 
cassette was digested from pBluescript with FseI and cloned into the FseI site of the 
pBac[3xP3-EGFPafm] vector [59,111]. The resulting vector was used for embryo 
microinjections to generate the VgDome line. 
Ae. aegypti Hop (AAEL012533) was PCR-amplified from cDNA in two 
segments: bp 1-1516 and bp 1517-3408. Each segment was separately cloned into 
pBluescript at the EcoRV site. The 5’ and 3’ segments were cleaved with EcoRI/SacI and 
SacI/SalI, respectively, and re-ligated into pBluescript at the EcoRI/SalI sites to obtain 




site downstream of Hop, and the AeVg promoter sequence was cloned at the 
XbaI/Klenow-filled site upstream of Hop. The AeVg-Hop-TrypT cassette was digested 
from pBluescript with FseI and cloned into the FseI site of the pBac[3xP3-DsRedafm] 
vector. The resulting vector was used for embryo microinjections to generate the VgHop 
line. 
To generate the VgDome transgenic line, 565 embryos were injected with the 
transformation vector and the phsp-pBac helper plasmid. Of these, 279 survived to 
adulthood and were backcrossed to WT Orl adults in 19 pools. G1 larvae were screened 
for GFP eye fluorescence (Figure 2.2), and one pool was found to contain positives.  
To generate the VgHop transgenic line, 613 embryos were injected with the 
transformation vector and the phsp-pBac helper plasmid. Of these, 132 survived to 
adulthood and were backcrossed to WT Orl adults in 10 pools. G1 larvae were screened 
for DsRed eye fluorescence (Figure 2.2), and one pool was found to contain positives.  
 Positive larvae were reared to adulthood and then intercrossed to G5 to ensure 
homozygosity of the transgene. PCR confirmation of each line was performed with the 
VgPro R and ITRR2’ primers for the VgDome line and the AeVgPro R and DsRed S 








Figure 2.2 Fluorescence screening of VgDome, VgHop, and hybrid VgDomexVgHop 
transgenic lines. VgDome line contains an eye-specific EGFP marker. VgHop line 
contains an eye-specific DsRed marker. The hybrid line contains eye-specific EGFP and 
DsRed markers. Fluorescence signals in the eyes of all the strains are indicated by orange 
arrows. 
 
Figure 2.3 PCR confirmation of the transgenic Ae. aegypti VgDome and VgHop 
lines. (A) PCR confirmation of the VgDome transgenic line. The arrow indicates an 
expected band at 3.6 kb. (B) PCR confirmation of the VgHop transgenic line. The arrow 
indicates an expected band at 2.9 kb. The following templates were used: Lane 2: 
Genomic DNA from the VgDome line; Lanes 3 and 9: Genomic DNA from WT Ae. 
aegypti; Lanes 4 and 10: No template; Lane 5: pBac[3xP3-EGFPafm-AeVg-Dome-
TrypT] plasmid; Lane 8: Genomic DNA from the VgHop line; Lane 11: pBac[3xP3-
DsRedafm-AeVg-Hop-TrypT] plasmid. Lanes 1, 6, 7: 1-kb ladder.  
 
To test susceptibility to DENV infection, both the VgDome and VgHop 
transgenic lines were introgressed with DENV-susceptible Rockefeller/UGAL (Rock) 
strain Ae. agypti for five generations. After five generations of outcrossing with the Rock 
strain, both the VgDome and VgHop transgenic lines were bred within the same strain for 
3 kb 





another five generations to ensure homogeneity. The WT Orl strain was mated with the 
Rock strain in parallel to serve as a control.  
 To generate a hybrid transgenic line over-expressing Dome and Hop 
simultaneously, male homozygous VgDome and female homozygous VgHop were mated 
in a ratio of 1:5. The offspring were then screened for the expression of both GFP and 
DsRed (Figure 2.2) and used for subsequent experiments to test their susceptibility to 
DENV. 
In the VgDome line, fat body expression of Dome was rapidly induced relative to 
WT, peaking as early as 6 hours post bloodmeal (hpbm) and again at 48 hpbm. Dome 
induction in the hybrid line followed a similar pattern, albeit with an approximately two-
fold higher peak at 6 and 24 hpbm (Figure 2.4). In the VgHop line, Hop expression was 
induced more gradually, peaking at 24 hpbm. Hop induction in the hybrid line followed a 
similar pattern, but with an earlier peak at 12 hpbm (Figure 2.4).  
Dengue virus restriction factor 1 (DVRF1; AAEL008492) is transcriptionally 
regulated by the JAK/STAT pathway, and encodes a putative anti-DENV effector 
molecule [12,59]. In the VgDome and VgHop lines, DVRF1 expression relative to WT 
peaked at 24 hpbm (Figure 2.4), indicating pathway activation. Interestingly, DVRF1 
expression was induced to similar levels in the hybrid line (Figure 2.4), suggesting that 





Figure 2.4 Transcript abundance of transgenes and effector genes in the fat body of 
VgDome and VgHop lines from before blood feeding (0 hr) up to 48 hpbm. Each bar 
represents relative fold change of Dome, Hop or DVRF1 gene compared between 
transgenic lines and WT Ae. aegypti. The S7 ribosomal gene was used to normalize 
cDNA templates. Error bars indicate standard error of the mean. Statistical analyses were 
performed using t-test using Prism software, *: p < 0.05, **: p < 0.01 compared to WT 
before blood feeding. 
 
Transgenic activation of the JAK/STAT pathway inhibits virus 
replication throughout the mosquito’s body 
We next investigated the effect of the transgene-mediated activation of the 
JAK/STAT pathway on DENV infection in the transgenic lines. Mosquitoes were first 
fed a naïve bloodmeal to activate the JAK/STAT pathway; two days later, they were 
orally infected with DENV2 via a second (infectious) bloodmeal. We determined 
DENV2 titers in the midguts at 7 day-post infectious blood meal (dpibm) (Figure 2.5A), 
in the carcasses (whole mosquito except midgut) at 14 dpibm (Figure 2.5B), and in the 
salivary glands at 21 dpibm (Figure 2.5C). VgDome and VgHop mosquitoes showed 
significantly lower midgut DENV2 titers than did the WT mosquitoes (a 78.18% and 
83.63% reduction in median titers for VgDome and VgHop, respectively). The VgDome 
and VgHop lines displayed a 87.37% and 94.21% reduction in median carcass DENV2 
titers, and more importantly, the transgenic mosquitoes also had a lower DENV2 titers in 
*	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the salivary glands (100% reduction in median salivary gland DENV2 titers for both lines 
when compared to WT).  
We orally infected VgDome and VgHop mosquitoes without prior activation of 
the JAK/STAT pathway in order to determine whether pathway activation at the time of 
infection was enough to grant systemic resistance. We found that the VgDome 
mosquitoes had comparable median midgut DENV2 titers, whereas the VgHop strain 
showed a 42.86% reduction in median midgut DENV2 titers (Figure 2.5D). We saw 
DENV2 resistance in the VgHop strain but not VgDome, suggesting that overexpression 
of the downstream component of the pathway can provide earlier protection against 
DENV infection. However, reduction of DENV titers in VgHop strain was not as strong 
as when compared to the VgHop mosquitoes that were given naïve blood meal before 
DENV infection. This result suggested that a naïve blood meal is required before the 
infectious blood meal to provide higher resistance to DENV infection, further suggesting 
that systemic immune activation by the JAK/STAT pathway is delayed.  
Although the hybrid line also displayed significantly lower DENV2 titers in the 
carcass compared to WT, these were not significantly different from the VgDome and 
VgHop lines (Figure 2.5E). Since no difference in DENV2 susceptibility was seen 
between the hybrid and the VgDome and VgHop transgenic lines, we chose to use only 
the VgDome or VgHop lines for subsequent experiments.  
 To confirm that the inhibitory activity of the JAK/STAT pathway on DENV 
infection is conserved among different DENV serotypes, we also challenged the VgDome 




more refractory to DENV4 infection compared to the WT (100% reduction in median 
carcass titers).  
 
Figure 2.5 Effect of JAK/STAT pathway activation on DENV infection in transgenic 
Ae. aegypti. The JAK/STAT pathway was induced in the transgenic lines by providing 
them a naïve blood meal; two days later, JAK/STAT-activated mosquitoes were orally 
infected with DENV2 or DENV4. DENV2 titers of the VgDome and VgHop lines were 
determined (A) in the midguts at 7 dpibm, (B) the carcasses at 14 dpibm, and (C) the 
salivary glands at 21 dpibm. (D) DENV2 titers in the mosquito midguts at 7 dpibm 
without prior activation of the JAK/STAT pathway through a naïve blood meal. (E) 
DENV2 titers of the JAK/STAT-activated hybrid VgDomexVgHop line in carcasses at 
14 dpibm. (F) DENV4 titers of the JAK/STAT-activated VgDome and VgHop lines in 
carcasses at 14 dpibm. WT mosquitoes were used as a control in parallel in all 
experiments. Horizontal red lines indicate medians. Statistical analyses were performed 
using either the Mann-Whitney test or Kruskal-Wallis test with Dunn’s post-test using 







Fitness impact of transgenic Dome and Hop mediated JAK/STAT 
pathway activation 
Activation of the immune system and transgenic over-expression of certain 
immune-related genes has been associated with fitness trade-offs [118,119,123] that 
could compromise the utility of a transgenic Ae. aegypti as a dengue control strategy. 
Transgenic activation of the JAK/STAT pathway may be particularly prone to fitness 
costs because it also functions in insect development [120-122,124]. For this reason, we 
examined the impact of introduction and expression of Dome or Hop under Vg promotor 
on the fitness of our transgenic lines. 
First we studied the impact of the introduction of Dome and Hop gene cassettes 
by measuring the longevity of male and female transgenic mosquitoes maintained on 
10% sucrose solution without a blood meal that would induce the transgene. In male 
mosquitoes, we found that the longevity of the VgDome line was comparable to that of 
the WT strain, while the longevity of the male VgHop line was slightly longer (by 4 
days) than that of the WT (Figure 2.6). The female VgDome and VgHop lines had 
longevities comparable to that of the WT, suggesting a minimal impact of these 
transgenes on the mosquito life span in the absence of a blood meal. Next, we examined 
the effect of blood meal-inducible transgene expression on female Ae. aegypti longevity. 
The longevity of the female VgDome and VgHop lines after blood feeding was 
comparable to that of the WT strain, suggesting minimal fitness effects on the mosquito 
life span when the JAK/STAT pathway is transiently activated. This minimal effect on 
longevity after transient activation of immune pathways was in concordance with 
previous studies, which activated the immune deficiency pathway (Imd) pathway in 






Figure 2.6 Effect of transgenes introduction and expression on mosquito longevity. 
Lifespans of male and female mosquitoes maintained on 10% sucrose solution or of 
female mosquitoes that were provided a blood meal to induce transgene expression. 
Statistical analyses of survival curve was performed using Log rank test with Prism 
software. ***: p < 0.001. 
Both VgDome and VgHop lines produced significantly fewer eggs compared to 
WT (Figure 2.7), suggesting that transgene introduction or expression compromises 
fecundity. The lower egg production is likely, at least in part, due to the competition 
between the vitellogenin promoter of the transgenes and the endogenous vitellogenin 
gene, as indicated by the lower expression level of the vitellogenin gene after blood 
feeding in the transgenic mosquitoes when compared to WT (Figure 2.8).  
 
Figure 2.7 Fecundity of the WT and transgenic Ae. Aegypti, as represented by number 
of eggs produced by each female mosquito. Statistical analyses were performed using the 






Figure 2.8 Expression of vitellogenin in the transgenic lines as compared to WT. 
mRNA levels were measured by real-time PCR, with ribosomal gene S7 as the 
normalization control. Error bars indicate standard error of the mean. Statistical analyses 
were performed using t-test using Prism software, *: p < 0.05 compared to vitellogenin 
gene expression in WT at 24 hours post blood meal. 
 
Immune-related transcripts are enriched upon JAK/STAT activation  
The JAK/STAT pathway-regulated antiviral effectors responsible for suppressing 
DENV infection are largely unknown, except for two genes, DVRF1 and DVRF2, that 
encode putative secreted and membrane-bound proteins, respectively, of unknown 
function [59,125]. To identify possible JAK/STAT pathway-regulated antiviral effectors 
and to assess the impact of transgenic JAK/STAT pathway activation on mosquito 
physiology at the molecular level, we used whole-genome oligonucleotide microarrays to 
compare the fat body transcriptomes of WT, VgDome, and VgHop lines at 24 hpbm 
(17,346 genes in the Ae. aegypti transcriptome). We selected the 24-h post-blood meal 
time point because of the DVRF1 peak expression at that time, suggesting the peak 
activity of the JAK/STAT. Genes that showed at least 1.68-fold (0.75 on a log2-scale) 
compared to WT were considered to be significantly differentially regulated. The log2-
fold difference in transcript abundance for each gene between VgDome or VgHop and 
WT mosquitoes is listed in Appendix 2, and the number and percentage of transcripts 
significantly regulated in each category are presented in Figure 2.9A and 2.9B. Genes 




commonly- or differentially-regulated in VgDome and Hop was represented in figure 
2.9C. As expected, DVRF1 transcripts were enriched in both lines relative to WT (see 
Appendix 2), an indication of pathway activation. In VgDome, 130 transcripts (0.75% of 
the whole transcriptome) were enriched compared to WT, and 71 (0.47%) were depleted. 
In VgHop, 254 transcripts (1.46%) were enriched compared to WT, and 204 (1.18%) 
were depleted. 
In both lines, IMM transcripts made up the largest specific class of enriched 
transcripts (excluding those with diverse (DIV) and unknown (UKN) functions).  Of the 
659 immune-related genes (IMM) in the Ae. aegypti transcriptome, 17 genes (2.58% of 
the total IMM genes) had a higher transcript abundance and 10 genes (1.52% of total 
IMM) had a lower transcript abundance in the VgDome line. In the VgHop line, 29 genes 
(4.40% of the total IMM) had a higher transcript abundance, and 15 genes (2.28% of total 
IMM) had a lower transcript abundance. The IMM had at least a 3-fold higher percentage 
of genes with higher transcript abundance when compared to the average percentage of 
regulated genes in the whole transcriptome. These results emphasize the importance of 
the JAK/STAT pathway in mosquito immune regulation and corroborate the fact that the 
VgDome and VgHop lines had higher immune activity than did the WT. IMM transcripts 
that are enriched upon JAK/STAT activation may encode potential DENV restriction 
factors (RFs) - gene products that inhibit DENV replication in the mosquito.  
Fifty transcripts were enriched and 18 were depleted in both VgDome and VgHop 
compared to WT (Figure 2.9 A, and C). Again, the IMM category was the largest specific 
class of transcripts that were enriched in both lines (9 genes, 1.37% of the total IMM). 




AAEL014390), three fibrinogen and fibronectin-related proteins (FBNs; AAEL006704, 
AAEL011400, and AAEL013417), two transferrins (TFs; AAEL015458, and 
AAEL015639), and a cathepsin b (CatB; AAEL015312).  
 
Figure 2.9. Transcriptomic profiles of the VgDome and VgHop mosquitoes. (A) 
Number of differentially expressed transcripts, classified according to functional groups 
as previously described [12,59,126]. Abbreviations: CS, cytoskeletal and structural; CSR, 
chemosensory reception; DIV, diverse functions; DIG, blood and sugar food digestive; 
IMM, immunity; MET, metabolism; PROT, proteolysis; RSM, redox, stress and 
mitochondrion; RTT, replication, transcription, and translation; TRP, transport; UKN, 
unknown functions. (B) Percentage of genes enriched or depleted in each functional 
group for the VgDome or VgHop line as compared to WT. (C) Venn diagram shows 
genes significantly regulated in VgDome and VgHop mosquitoes. Green arrows and 
circle represent VgDome strain, and red arrows and circle represent VgHop strain. 
Upward arrows represent genes significantly enriched, downward arrows represent genes 














































Table 2.1 List of top ten enriched and depleted transcripts shared between VgDome 
and VgHop lines compared to WT 
Gene ID Description Functional group VgDome VgHop 
AAEL007703 conserved hypothetical protein U 3.215 3.352 
AAEL011400 conserved hypothetical protein I 2.634 2.21 
AAEL005482 conserved hypothetical protein I 2.369 2.205 
AAEL010196 trypsin PROT 2.031 2.224 
AAEL000986 NADH-ubiquinone oxidoreductase ashi subunit RSM 2.027 2.067 
AAEL002860 conserved hypothetical protein D 2.016 1.633 
AAEL012605 conserved hypothetical protein D 2.008 1.699 
AAEL005106 conserved hypothetical protein U 1.749 0.958 
AAEL008492 conserved hypothetical protein U 1.721 1.275 
AAEL013417 fibrinogen and fibronectin I 1.584 1.708 
AAEL015337 
neutral alpha-glucosidase ab precursor 
(glucosidase ii alpha subunit) (alpha 
glucosidase 2) 
M -0.967 -2.407 
AAEL010097 nuclein acid binding D -1.149 -1.591 
AAEL014937 hypothetical protein U -0.945 -1.289 
AAEL002554 anosmin, putative D -1.466 -1.099 
AAEL002652 hypothetical protein U -1.234 -1.081 
AAEL017491 hypothetical protein U -1.251 -1.001 
AAEL013734 hypothetical protein U -1.287 -0.987 
AAEL009962 hypothetical protein D -1.241 -0.96 
AAEL008595 conserved hypothetical protein D -1.162 -0.953 
AAEL007458 amino acid transporter TRP -0.833 -0.945 
 
Pattern recognition receptors (PRRs) are important molecules responsible for 
binding and recognition of pathogen-associated molecular patterns (PAMPs). PRR for 
DENV in Ae. aegypti mosquitoes has yet to be identified. Transcriptomic analyses 
showed that transcripts of CLEC and FBN, gene families with potential function as 
PRRs, were enriched in VgDome and VgHop mosquitoes compared to the WT. CLECs 
have carbohydrate binding properties, and serve as PRR molecules. In Drosophila, 




encapsulation processes [124,128]. In Ae. aegypti, several CLEC have been reported to 
function as receptors for DENV entry into cells [125,129]. However, none of the CLEC 
identified in our study were reported as a receptor for virus entry. Silencing of 
AAEL005482 had no effect on DENV infection, whereas silencing of a homolog of 
AAEL014390 resulted in a non-significant increase in DENV loads, by 1.48-fold 
[40,125]. AAEL011610 has not been tested for its role in DENV replication, but has been 
reported to be up-regulated in transgenic Ae. aegypti over-expressing Rel2, transcription 
factor for the Imd pathway, under the control of the vitellogenin promoter [126,130]. 
FBNs are thought to serve as PRRs in Drosophila and in Anopheles mosquitoes 
[127,131] [126,128]. but their function in Ae. aegypti has yet to be elucidated.  
CatB is a family of lysosomal cysteine proteases with functions in TLR signaling 
as well as T and B cell apoptosis [12,59,129]. One of the CatBs regulated in our study 
(AAEL007585) has been reported to facilitate DENV infection in Ae. aegypti salivary 
glands [40,41,44]; it was hypothesized that CatB-mediated apoptosis may facilitate cell-
to-cell spread of the virus.  
Over-expression of Dome and Hop also regulated specific subsets of IMM 
transcripts (Appendix2). Eight IMM genes were enriched in the VgDome but not in the 
VgHop, including three serine proteases (AAEL003279, AAEL000030, and 
AAEL006434), two Niemann-Pick Type C2 molecules (AAEL012064, and 
AAEL004120), a cathepsin b (AAEL007599), and a lysozyme C (AAEL017132). 
Twenty IMM transcripts were enriched in VgHop but not in VgDome. These included 
four cathepsin b genes (AAEL009637, AAEL009642, AAEL007585, and AAEL012216), 




thioester-containing protein (TEP22; AAEL000087), and several anti-microbial peptides 
(AMPs) such as cecropins (AAEL000621, AAEL000625), defensins (AAEL003832, 
AAEL003841), a gambicin (AAEL004522), and a lysozyme P (AAEL003723). These 
line-specific transcripts suggest complexities in JAK/STAT pathway regulation, and 
different as-yet unknown branches of the pathway and fine-tuning mechanisms may 
come into play to regulate different subsets of genes. 
TEPs, which encode complement factor-like proteins belonging to the alpha-2-
macroglobulin family, play important roles in insect immunity [12,130]. In Ae. aegypti, 
TEP22 was previously reported to be regulated by the CTL CLSP2  (AAEL011616), and 
to be involved in the mosquito's anti-fungal response [54,131-133]. TEP22 was also up-
regulated in transgenic Ae. aegypti over-expressing the Toll pathway transcription factor 
Rel1 [93,126], suggesting that there may be crosstalk between these two immune 
pathways, both of which both play an important role in anti-DENV responses [12,59,97]. 
In further support of this, several AMPs belonging to the defensin and cecropin families 
were up-regulated in our JAK/STAT transgenic strains and have been previously studied 
with regard to their anti-DENV properties [41,44,134]. Gambicin was previously 
described to be regulated by the Toll pathway [12,134,135]; however, it has never been 
tested for anti-DENV activity.  
Because we observed regulation of several AMPs, in both the VgDome and 
VgHop lines, that might provide protection against bacterial infection, we challenged 
these mosquitoes with a Gram-negative bacterium, Pantoea spp., and a Gram-positive 
bacterium, Bacillus cereus. We found no resulting differences in mortality between the 





Figure 2.10. Mortality of the VgDome and VgHop lines from bacterial infection. 
Mosquitoes were challenged with Pantoea spp. or Bacillus cereus, with PBS as a 
negative control. Survival analysis was performed using Data are from three independent 
replicates. 
 
Transcript abundances of potential DENV host factors were depleted 
upon JAK/STAT activation 
Other than the IMM genes, hundreds of transcripts in other functional classes 
were differentially expressed in VgDome and VgHop compared to the WT. (Figure 
2.9A). This result is not unexpected since the JAK/STAT pathway plays important roles 
in other biological processes such as cell development and homeostasis, as well as lipid 
metabolism [54,95,132,133].  We also found that genes with unknown function 
contributed to a large proportion of top shared enriched and depleted genes shared 
between VgDome and VgHop compared to WT (3 out of 10 enriched transcripts, and 4 
out of 10 depleted transcripts). These data show that our knowledge is still limited on the 
function of the JAK/STAT pathway in Ae. aegypti.  
The transcript abundances of several previously reported putative DENV host 
factors (HFs; genes that facilitate virus replication in the host) were significantly depleted 
in the transgenic lines compared to WT; a pattern that could potentially result in a 




Glucosidase 2 alpha subunit (aGluc; AAEL015337) transcripts were depleted in 
VgDome and VgHop (0.967- and 2.407-fold in log2 scale, respectively). aGluc has been 
identified in a high-throughput screen as a DENV HF in both HuH-7 human and D.Mel-2 
Drosophila cells [93,136,137]. We previously identified aGluc as putative HF from 
transcriptomic comparisons between DENV-refractory and -susceptible strains, but 
silencing of aGluc had no effect on DENV infection in Ae. aegypti [97,132]. 
Nevertheless, previous studies have suggested that aGluc is required for proper 
glycosylation of the viral glycoproteins PrM and E [134,138], and chemical inhibition of 
aGluc results in lower virus production from infected cells [134,135,139]. It is possible 
that the transient silencing of aGluc by RNAi in the previous study was not sufficient to 
deplete aGluc at the protein level, and therefore no effect was observed.  
Transcripts of vacuolar ATP synthase subunit ac39 (vATPase-ac39; 
AAEL0011025) were depleted in VgHop compared to WT (2.707-fold in log2 scale). Cell 
entry, a crucial step in DENV infection, requires acidification of endosomes by vATPase 
enzymes. Knockdown of vATPase-ac39 and several other vATPase subunits, as well as 
chemical inhibition of vATPase activity with bafilomycin, have been shown to inhibit 
DENV replication in Ae. aegypti [95,140,141]. 
Lipid homeostasis and trafficking play important roles in the replication of 
DENV, an enveloped virus. DENV is thought to facilitate its replication by altering the 
expression of lipid binding proteins and enzymes involved in lipid biosynthesis, such as 
fatty acid synthases and Niemann-Pick type C protein family members 
[136,137,142,143]. The JAK/STAT pathway has previously been shown to influence 




[132,144,145]. In VgHop, sterol carrier protein 2 (SCP2; AAEL012697) transcripts were 
depleted compared to WT (3.624-fold in log2 scale). SCP2 encodes an intracellular sterol 
carrier protein that facilitates cholesterol uptake in Ae. aegypti cells [138,146]; 
knockdown or chemical inhibition of SCP2 was recently shown to inhibit DENV 
replication in Ae. aegypti Aag2 cells [44,47,139]. 
Transcripts of the DEAD-box ATP-dependent RNA helicase (DDX; 
AAEL004978) gene were depleted in both VgDome and VgHop (0.70- and 0.79-fold in 
log2 scale, respectively). DDX gene family plays important cellular functions in 
transcription, mRNA transport, and translation [140,141,147]. DDX gene family 
members are required for viral replication in hepatitis C virus (HCV) [142,143,148,149], 
retroviruses [59,144,145,150], and Japanese encephalitis virus [74,146,151]. DDX 
proteins are used by these viruses to regulate the translational machinery and for viral 
RNA transport to favor virus replication. However, the role of this gene family in DENV 
replication has not yet been studied in Ae. aegypti. 
 
Functional analysis of JAK/STAT pathway-regulated putative DENV 
restriction factors and DENV host factors using RNA interference 
Our transcriptomic analysis of the VgDome and VgHop lines yielded candidate 
genes with potential function as DENV restriction factors (RFs) or host factors (HFs). We 
selected candidate genes based on their expression patterns and previous reports of their 
gene function. Based on their expression patterns (enriched in transgenic lines) and 
previous reports of their gene function, we selected five candidate RFs from enriched 




Ukn566)) and two candidate HFs from depleted genes (DDX and SCP2) for further 
characterization using RNAi-mediated gene silencing assays (Table 2.2). 
 
Table 2.2. List of candidate RFs and HFs for functional confirmation by RNAi  
 
Ukn7703 (AAEL007703) transcripts were very highly enriched in the transgenic 
lines compared to WT (3.215-, and 3.352-log2 fold higher in VgDome and VgHop 
respectively). The gene has also been reported to be induced in two strains of Wolbachia-
infected Ae. aegypti [44,47,59,152], and is conserved among Aedes, Culex, and 
Anopheles mosquitoes (Figure 2.11), suggesting an important role in mosquito biology. 
Ukn7703 encodes a putative secreted protein with a C-terminal beta-propeller domain 
distantly related to WD-40 repeats (predicted using NCBI conserved domain search 
[147,153]). WD-40 domains are involved in protein-protein interactions in several 






Figure 2.11. Phylogenetic tree of orthologs of AAEL007703 gene obtained from 
Vector base.  
URL: https://www.vectorbase.org/Multi/GeneTree/Image?gt=VBGT00190000016830 
 
Figure 2.12 Silencing efficiencies for candidate RFs and HFs. 
 
Ukn566 (AAEL000566) transcripts were enriched in both VgDome and VgHop 
compared to WT (0.946- and 1.748-log2 fold, respectively); this gene was also induced in 




protein using TMHMM software [59,74,151]. While no predicted protein domains were 
detected, Ukn566 and its orthologs share conserved cysteine positions. Cysteine repeats 
have previously been reported to be important for the three-dimensional structure and 
function of receptor proteins such as LDL [59,74,152] and scavenger receptors [59,153]. 
Potential functions of the remaining candidate genes have been discussed in the previous 
section. 
Across the candidate genes, silencing efficiencies varied from 22% to 85%, as 
shown in Figure 2.12. Our screen confirmed Ukn7703 as a putative RF (31.82% increase 
in median DENV titer when compared to the GFP dsRNA-injected group), and SCP2 as a 
putative HF (85.71% decrease in DENV titer when compared to the GFP dsRNA-injected 
group) (Figure 2.13). Silencing of DDX also reduced the DENV2 titers in the carcass by 
61.43%, although this result was not statistically significant by a small margin 
(p=0.0555). The lack of statistical significance may be a result of the lower silencing 
efficiency (22%) achieved for this gene. Because of the limitation of RNAi in failing to 
completely knock down a gene of interest, the lack of effects on DENV infection for the 






Figure 2.13 Effect of putative host and restriction factor silencing on DENV 
susceptibility. DENV2 titers at 14 dpibm in the carcasses (whole mosquito body except 
midgut) of the WT Ae. aegypti after silencing of the putative HFs or RFs, compared to 
GFP dsRNA-injected control. Data are a pool of three biological replicates, and statistical 




We have demonstrated that we can induce activation of the JAK/STAT pathway 
by over-expressing JAK/STAT pathway receptor Dome and the Janus kinase Hop under 
the control of Vg promoter. Overexpression of Dome and Hop prior to exposure to 
DENV systemically controls DENV infection. Since Dome and Hop were over-expressed 
specifically in the fat body, the reduction of DENV titers in the midgut suggested that the 
JAK/STAT pathway functions as a systemic anti-viral defense system in Ae. agypti, and 
may possibly prime uninfected cells and other immune cells to assume an antiviral state. 
This type of systemic activation in the mosquito is analogous to the mammalian 




the systemic immune response function of the JAK/STAT pathway in Drosophila 
[97,148]. 
A comparable level of DENV infection was found in the hybrid line compared to 
VgDome or VgHop, suggesting the existence of a limiting factor downstream of Dome 
and Hop, a possibility that is in agreement with the results concerning the induction of the 
DVRF1. It will be an interesting attempt to further reduce the vector competence for 
DENV by generating transgene constructs expressing both receptor and downstream 
pathway molecules such as STAT. Availability of JAK/STAT pathway downstream 
components might not be the only limiting factor of pathway activation.  The JAK/STAT 
pathway is negatively regulated by PIAS or suppressor of cytokine signaling (SOCS) 
proteins to prevent overactivation of the pathway [54], and we have previously shown 
that silencing PIAS activates the JAK/STAT pathway and inhibits DENV infection 
[59,156]. To improve JAK/STAT pathway activation in transgenic mosquitoes, we can 
generate a transgene construct that contains the receptor gene together with a hairpin 
double-stranded RNA sequence complementary to PIAS or SOCS to reduce the level of 
negative regulator molecules. 
We also showed that both transgenic lines were refractory to DENV2 and DENV4 
infection compared to the WT, which suggests that the anti-viral function of the 
JAK/STAT pathway is conserved across different DENV serotypes. It will be interesting 
to determine if JAK/STAT pathway activation is also effective against other mosquito-
borne flaviviruses such as the West Nile, zika, and yellow fever virus, as well as against 




Analyses of the fitness impact from transgene expression in the transgenic lines 
showed that there was a minimal disadvantage to the longevity of these mosquitoes, but 
there was a negative impact on fecundity for both transgenic lines. It should be noted that 
these mosquitoes were maintained under laboratory conditions with an abundant food 
supply and minimal environmental stress. The assays may therefore not reflect the effect 
of transient JAK/STAT pathway activation on mosquito longevity in a natural setting 
where a myriad of stressors can apply. Additional experiments will be necessary to fully 
evaluate the effect of transient JAK/STAT pathway activation on longevity in natural 
settings. Reduced egg production and lower expression of vitellogenin gene have also 
been observed in transgenic An. stephensi lines using the Vg promoter to drive gene 
expression of Imd pathway component [74,97]. This phenomenon; however, was not 
observed in transgenic An. stephensi that overexpressed Imd pathway component under a 
regulation of bloodmeal inducible, gut-specific carboxypeptidase promoter. These results 
suggest that the use of Vg promoter compromises mosquito’s fecundity, which suggests 
that alternative fat body-specific promoters may be required to help to minimize fitness 
disadvantages. 
Transcriptomic comparisons between the fat body of blood-fed transgenic 
mosquitoes and WT allowed us to identify genes that influence DENV infection in Ae. 
Aegypti. The greater resistance to DENV infection displayed by the transgenic lines was a 
result of a combination of a higher transcript abundance of RFs and a lower transcript 
abundance of HFs. These multifactorial factors for DENV resistance make it harder for 





Even though several AMPs were enriched in the transgenic lines compared to the 
WT, we did not observe differences in mosquitoes’ mortality from bacterial infection 
This result was similar to what we observed in a previous study: that the transient 
silencing of PIAS, a negative regulator of the JAK/STAT pathway, has no effect on 
mosquito mortality resulting from bacterial infection [59,97]. It is also possible that the 
regulated AMPs may have more specialized anti-DENV function or may not have anti-
microbial activity against the particular bacteria used in our study. A previous study of 
defensins from humans has also suggested that the anti-bacterial activity of certain AMPs 
is highly specific [85,155]. Future extensive study of the anti-bacterial function of these 
AMPs will require recombinant expression of individual AMPs so they can be tested with 
a wide panel of bacteria.  
 
In summary, our study is the first to provide a proof-of-concept that genetic 
engineering of the mosquitoes’ JAK/STAT immune pathway can be used to render the 













Identification of putative host and restriction factors that 
contributes to refractoriness to DENV infection among 
laboratory and field-derived Aedes aegypti mosquitoes 
 
Parts of this work were published in: 
Sim S, Jupatanakul N, Ramirez JL, Kang S, Romero-Vivas CM, Mohammed H, et al. 
Transcriptomic profiling of diverse Aedes aegypti strains reveals increased basal-
level immune activation in dengue virus-refractory populations and identifies novel 
virus-vector molecular interactions. Plos Neglect Trop D. 2013;7: e2295–e2295. 
doi:10.1371/journal.pntd.0002295 
Kang S, Shields AR, Jupatanakul N, Dimopoulos G. Suppressing dengue-2 infection by 








Our lab has previously established a panel of laboratory and field-derived Ae. 
agypti strains from different geographical origins. We have shown that these mosquito 
strains vary in susceptibility to DENV infection, and comparative genome-wide gene 
expression microarray-based analysis revealed higher basal levels of numerous 
immunity-related gene transcripts in DENV-refractory mosquito strains compared to 
susceptible strains. Here we used RNA interference-mediated gene silencing assays to 
further confirm functions of the Toll, Imd, JAK/STAT, and RNAi-pathway in 
contribution to refractoriness in different strains. By correlating transcript abundance 
patterns with DENV susceptibility, we also identified new candidate modulators of 
DENV infection in the mosquito, and we provide functional evidence for vATPase 
subunits as DENV host factors. Our comparative transcriptome dataset thus not only 
provides valuable information about immune gene regulation and usage in natural 
refractoriness of mosquito populations to dengue virus but also allows us to identify new 









Mosquitoes, like other organisms, are exposed to a variety of microbes in their 
natural habitats and possess an innate immune system that is capable of mounting a 
potent response against microbial challenge. However, studies of mosquito immune 
responses to DENV and other human pathogens have largely been performed in 
laboratory strains of Ae. aegypti, which have been maintained under insectary conditions 
for many generations. As compared to natural mosquito populations, laboratory mosquito 
strains are exposed to lower doses and a much narrower range of microbes, constant 
temperature and humidity; together with the genetic bottleneck of a small initial parental 
population size, this often results in a loss of genetic variability. However, differences 
between laboratory-maintained mosquitoes and field populations have been poorly 
studied.  
In this study, we collected Ae. aegypti from different DENV-endemic 
geographical locations as well as laboratory-maintained Ae. aegypti strains [20,97], and 
showed that they have a wide range of DENV susceptibility and different transcriptomic 
profiles. These mosquito strains and transcriptomic dataset served as powerful tools to 
dissect interactions between DENV and to identify novel modulators of DENV infection 
in Ae. aegypti.  
 
MATERIALS AND METHODS 
Mosquito rearing and cell culture conditions 
Mosquitoes were maintained on a 10% sucrose solution in insectary condition at 




line was maintained in MEM (Gibco) supplemented with 10% heat-inactivated FBS, 1% 
L-glutamine, 1% non-essential amino acids, and 1% penicillin-streptomycin at at 32°C 
and 5% CO2. BHK-21 hamster kidney cells were maintained on DMEM (Gibco) 
supplemented with 10% FBS, 1% L-glutamine, 1% penicillin-streptomycin, and 5 ug/ml 
Plasmocin (Invivogen) at 37°C and 5% CO2.  
Oral DENV infections in Ae. aegypti  
Mosquito infections with DENV were carried out by oral infection as previously 
described [97,156]. The New Guinea C strain of DENV2 was propagated in C6/36 cells 
as previously described [12]. Briefly, DENV2 was infected to C6/36 cells seeded to 80% 
confluence at a multiplicity of infection (MOI) of 3.5 and incubated at 32°C and 5% CO2 
for 6 days. The infected cells were then harvested and lysed through 3 cycles of freezing 
and thawing between dry ice and 37°C water bath. The propagation yielded a virus titer 
of between 106 and 107 PFU/ml. Then DENV was mixed 1:1 v/v with commercial human 
blood and supplemented with 10% human serum and 1 mM ATP. The bloodmeal was 
then offered to mosquitoes via an artificial membrane feeding system. Midguts were 
dissected at 7 days post-blood meal (dpbm) and stored individually in DMEM at -80°C 
until titrated by plaque assay. 
Gene silencing assays 
 Silencing of candidate hotst and restriction factor genes was performed through 
RNA interference (RNAi)-mediated gene silencing as previously described. Field-derived 
mosquitoes used in these assays were from generations F5 to F13, depending on the 
strain. Each experiment was performed with mosquitoes from the same generation to 




female mosquitoes were cold-anesthetized and individually injected with 200 ng of 
dsRNA specific for the target gene of interest, and GFP dsRNA was used as control in all 
experiments. The dsRNA-injected mosquitoes were then orally infected with DENV2- 
supplemented blood at 3-4 days post-dsRNA injection. Midguts were dissected at 7 dpbm 
for DENV titration by plaque assay. dsRNA was synthesized using the HiScribe T7 in 
vitro transcription kit (New England Biolabs). Primer sequences used for dsRNA 
synthesis and to confirm gene silencing by real-time PCR are presented in the 
Appendix1. Due to high sequence identity, it was unavoidable that dsRNA against 
AAEL010429 also targeted AAEL013577 and AAEL010436 (also putative insect 
allergen family members), and dsRNA against AAEL015337 also targeted AAEL010599 
(also a neutral alpha-glucosidase ab precursor). We cannot however exclude the 
possibility that these seemingly different transcripts represent the same gene, due to 
possible genome sequence annotation errors.  
DENV titration by plaque assay 
 DENV2 titers in the mosquito midguts were determined by plaque assay on BHK-
21 cells. Individual midguts were homogenized in DMEM using glass beads with a Bullet 
Blender homogenizer (NextAdvance), 10-fold serially diluted, and then inoculated onto 
BHK cells seeded to 80% confluence in 24-well plates. Plates were rocked for 15 min at 
room temperature, and then incubated for 45 min at 37°C and 5% CO2. Each well was 
then overlayed with 1 ml of DMEM containing 2% FBS and 0.8% methylcellulose and 
plates were incubated for 5 days at 37°C and 5% CO2. Plates were fixed with a methanol 








Laboratory and field-derived Ae. aegypti strains have different degrees 
of DENV2 susceptibility  
 Our lab has established a panel of field-derived and laboratory strains Ae. aegypti 
strains obtained either through generous contributions from collaborators or our own field 
collections (Table 3.1). Field locations were selected to represent geographically distinct 
dengue-endemic regions spanning South America, the Caribbean, and Southeast Asia, 
and laboratory strains were included to allow us to compare DENV susceptibility 
between laboratory maintained and natural mosquito populations. 
To assess their susceptibility for DENV, we orally infected each mosquito strain 
with DENV2 and assessed midgut virus titers at 7 dpbm. The highly susceptible 
Rockefeller (Rock) laboratory strain typically used in our group’s experiments served as 
a basis for comparison. To compare susceptibility to DENV2 infection, we calculated the 
relative infection level of each strain by calculating its median DENV2 titer as a 
percentage of the median titer of its respective Rock control. We found that Orl, Waco, 
PFin, PR, PTri, and BKK had significantly lower midgut DENV2 titers as compared to 
Rock, and median virus titers in Kitts were four-fold lower than in Rock (Figure 3.1). 
SIN was the only strain with midgut DENV2 titer comparable to Rock strain. Among 
these Ae. aegypti strains, the SIN and PTri strains were the most susceptible, while BKK 





Table 3.1 Origins and name abbreviations of laboratory and field-derived Ae. 
aegypti strains [93,97]. 
 
 
Figure 3.1 Susceptibilities of Ae. aegypti strains to DENV2 infection. Relative median 
DENV2 midgut infection levels at 7 days post-bloodmeal (dpbm) for each Ae. aegypti 
strain, compared to the Rockefeller strain. Statistical analyses performed by using Mann-








Mosquito immune signaling pathways and the RNAi pathway control 
DENV2 infection to different degrees in various Ae. aegypti strains 
 Transcriptomic analyses by whole genome microarray assays revealed that 
differences in basal levels of immune related gene (IMM) transcript abundance among 
mosquito strains is an important factor in determining susceptibility to DENV [93,97].  
These IMM are likely to be regulated by major immune signaling pathways, the Toll, 
IMD, and JAK/STAT pathways, which regulate the mosquito immune response to a 
variety of pathogens [32].  We examined the contributions of these pathways to 
refractoriness in these strains. In addition, since the RNAi pathway is an important 
controller of DENV infection in Ae. aegypti [85,92], we also examined its role in this 
regard. Each pathway was inhibited or activated through the RNAi-mediated knockdown 
of a key pathway component or regulator, and the effect of this manipulation on midgut 
DENV2 titers was assessed. 
 In the Orl strain, individually compromising the Toll, IMD, JAK/STAT, and 
RNAi pathways via knockdown of MyD88, IMD, Dome, and Dcr2, respectively, resulted 
in a significant and dramatic increase in midgut DENV2 titers to a level that was 
comparable to what typically seen in Rock  (Figure 3.2A), suggesting that each of these 
pathways is a major contributor to the refractoriness seen in Orl. In the BKK strain, 
compromising the Toll, IMD, JAK/STAT or RNAi pathways only resulted in a non-
significant 3- to 5-fold increase in midgut virus titers (Figure 3.2A), suggesting the action 
of BKK strain-specific DENV restriction factor(s) that operate independently of these 
pathways (Figure 3.2A).  
 Conversely, activating immune signaling pathways by silencing pathway negative 




infection (Figure 3.2B). In agreement with our previous studies [20,93,94], silencing the 
Toll and JAK/STAT pathway negative regulators Cactus and PIAS in the Rock strain 
resulted in a significant decrease in midgut DENV titers, while silencing the IMD 
pathway negative regulator Caspar resulted in a non-significant decrease (Figure 3.2B). 
As expected, silencing Cactus in the SIN strain also resulted in a significant decrease in 
virus titers, but no effect was seen for PIAS or Caspar. It is possible that the JAK/STAT 
and IMD pathways are already operating at maximum capacity, especially given the high 
viral load observed in this strain, or that the SIN strain possesses factors acting 
independently of these pathways that facilitate DENV infection. From these data, we 
speculate that the basal activation levels of immune pathways may be higher in refractory 
mosquitoes, and that these elevated levels in refractory strains may contribute to 






Figure 3.2 Contributions of the Toll, Imd, JAK-STAT, and RNAi pathways to the 
control of DENV2 in refractory and susceptible mosquito strains. Midgut DENV2 
titers at 7 dpbm in (A) MyD88, Imd, Dome, and Dcr2-silenced Orl and BKK mosquitoes, 
and (B) Cactus, Caspar, and PIAS-silenced Rock and SIN mosquitoes. Data are a pool of 
at least three independent biological replicates. ****, p<0.0001; ***, p<0.001; **, 








Transcriptomic comparison between refractory and susceptible Ae. 
aegypti reveals candidate DENV restriction and host factors 
Other than immune-related transcripts, genes in other functional groups can also 
influence DENV infection in different fashion. DENV host factors (HFs) are host genes 
that the virus uses to facilitate its infection or are required to complete its replication 
cycle. To identify putative HFs, hierarchical cluster analyses of the transcriptomes were 
performed between the two most refractory (Orl, BKK) and the two most susceptible 
(PTri, SIN) mosquito strains (Figure 3.3).  In addition to expanding our limited 
knowledge of molecular interactions between DENV and Ae. aegypti mosquitoes, this 
analysis also offered the potential to identify molecular determinants that affect vector 
competence in field mosquitoes.  
 
Figure 3.3 Identification of novel candidate DENV host factors through hierarchical 
clustering. Selected gene clusters obtained through hierarchical clustering of the midgut 
transcriptomes of the two most refractory (Orl, BKK) and two most susceptible (PTri, 
SIN) Ae. aegypti strains. Genes that displayed differentially abundant transcripts in at 
least two of the four strains were included in the analysis. Red and green indicate 





 Hierarchical clustering in the midgut revealed potential gene cluster for host 
factors that had lower transcript abundance in the refractory Orl and BKK strains but 
higher transcript abundance in the susceptible PTri and SIN strains (Figure 3.3A). The 
cluster consisted of a vacuolar ATP synthase (vATPase) subunit G (AAEL012819), a 
glucosyl/gluronosyl transferase (AAEL003099), a putative high mobility group non-
histone protein (AAEL011414), and three hypothetical protein genes that encoded insect 
allergen repeats domain structure (AAEL013577, AAEL010436, and AAEL010429). 
 
Functional characterization of selected candidate DENV host factors 
 We selected three candidate DENV host factors identified through hierarchical 
clustering for functional analysis in the susceptible Rock, PTri, and SIN mosquito strains 
(Table 3.2) and hypothesized that knockdown of these genes via RNAi-mediated gene 
silencing would render mosquitoes more refractory to DENV.  
Table 3.2 Candidate DENV host factors selected for functional characterization via 
RNAi-mediated gene silencing. 
Gene ID Name Functional group Orl BKK P Tri SIN 
AAEL011414 high mobility group non-histone protein M -0.83 -0.83 0.82 0.53 
AAEL003099 glucosyl/glucuronosyl transferases M -1.34 -0.54 1.01 0.66 
AAEL016980 Hypothetical protein U -0.77 -0.29 1.71 1.92 
AAEL017468 hypothetical protein U -0.79 -1.72 0.54 1.03 







Knockdown of the vATPase subunit G gene (AAEL012819) resulted in 
significantly reduced midgut DENV titers in both the Rock and PTri strains and a non-
significant decrease in the SIN strain, suggesting that it does indeed function as a DENV 
host factor (Figure 3.4). Surprisingly, knockdown of the gene encoding a HMGB protein 
(AAEL011414) resulted in a significant increase in SIN strain DENV titers, but it had no 
effect in the other two mosquito strains (Figure 3.4). Knockdown of the putative insect 
allergen had no effect in any of the strains.  
 Our panel of Ae. aegypti strains is also an excellent platform for characterizing or 
validating candidate DENV host factors identified through other screening 
methodologies. Sessions et al. (2009) identified numerous candidate DENV host factors 
by performing a high-throughput RNAi screen in Drosophila cells [12,59,93]. We 
selected the Ae. aegypti orthologs of three hits from this study for functional 
characterization in our susceptible mosquito strains. Only the knockdown of 
AAEL002430, which codes for an N-acetylglucosamine-6-phosphate deacetylase, 
resulted in significantly decreased DENV titers in the Rock strain but not in the SIN or 







Figure 3.4 Effect of candidate DENV host factor knockdown on midgut DENV2 
titers in susceptible Ae. aegypti strains. Midgut DENV2 titers at 7 dpbm, and data are a 
pool of at least three independent biological replicates. **, p ≤ 0.01 *, p ≤ 0.05 compared 





Figure 3.5 Effect of candidate DENV host factor selected from high-througput 
screen knockdown on midgut DENV2 titers in susceptible Ae. aegypti strains. Data 
are a pool of at least three independent biological replicates. **, p ≤ 0.01 *, p ≤ 0.05 




vATPase subunits are important DENV host factors in Ae. aegypti 
  In addition to our results, previous high-throughput screening for insect and 
human DENV host factor suggested that several vATPase subunits might serve as DENV 
host factors in the mosquitoes [93,97,157]. In the previous section, vATPase subunit g 
(vATP-g: AAEL012819) was experimentally confirmed as a host factor; however, the 
requirement of other subunits on DENV replication was unknown. We performed RNA-
mediated gene silencing on more vATPase subunits to confirm that the function of the 
whole vATPase enzyme complex, not just the vATP-g as DENV host factors. The knock 
down of vATPase subunits ac39 (vATP-ac39), and vATPase subunits V0B (vATP-V0B) 
resulted in a reduction in midgut DENV titers in all the mosquito strains tested ranging 





Figure 3.6 Effect of vATPase subunits knockdown on midgut DENV2 titers in 
susceptible Ae. aegypti strains. Data are a pool of at least three independent biological 
replicates. **, p ≤ 0.01 *, p ≤ 0.05 compared to dsGFP-treated mosquitoes in Dunn’s 










A major finding of this study is that we confirmed the role of the Toll, JAK-
STAT, and IMD pathways in controlling DENV infection in refractory Ae. aegypti 
strains. Our results indicate that basal levels of mosquito immunity influence vector 
competence, in addition to other factors, such as the availability of receptors or host 
factors required for virus infection and replication. While these may seem to be obvious 
conclusions, determinants of vector competence in natural mosquito populations have 
been very poorly studied, and the idea of a basal level of immunity is not necessarily a 
given. 
The importance of classical immune pathways varies among strains as we 
observed that activation of the JAK/STAT pathway resulted in a decreased midgut 
DENV2 titers in Rock but not SIN strain. Similarly, inhibition of immune pathways in 
BKK strain also results in a weaker increase of DENV2 midgut titers when compared to 
the inhibition of the immune pathways in Orl strain. These results emphasized that there 
is a natural variation in how each immune pathway contributes to DENV susceptibility.  
Our data also suggest that while the major immune signaling pathways play a key 
role in determining DENV susceptibility in both laboratory- and field-derived 
mosquitoes, strain-specific factors acting independently of these pathways are also likely 
to make important contributions. This panel of Ae. aegypti strains also allowed us to 
functionally characterize several candidate DENV host factors, which were selected 
because they displayed increased transcript abundance in susceptible strains but 




RNAi-mediated knockdown of the vATPase subunit G gene (vATP-g, 
AAEL012819) rendered susceptible mosquito strains more refractory to midgut DENV2 
infection, suggesting that it does indeed function as a DENV host factor. In the vATPase 
complex, subunit G is part of a peripheral stalk connecting the peripheral domain (which 
catalyzes ATP hydrolysis) and the integral domain (through which protons are 
translocated), and it may play the role of stator in the rotary machinery. In yeast, deletion 
of subunit G leads to complete loss of assembly of the complex [92]. In our dataset, 
vATP-G was the only subunit to show a clear pattern of enriched basal-level transcript 
abundance in susceptible strains. However, functional assays of other vATPase subunits 
as DENV host factors by RNAi-mediated gene silencing suggested that the function of 
vATPase enzyme as a whole complex is required for efficient DENV infection in Ae. 
aegypti. Moreover, we observed the effect across laboratory-adapted and field-derived 
mosquito strains emphasizing a crucial role of this enzyme complex in facilitating DENV 
infection. vATPases are multisubunit enzymes found in the membranes of endosomes, 
lysosomes, and secretory vesicles that bring about the acidification of these organelles via 
an ATP-dependent rotary mechanism that drives proton transport [92,98,99,158,159]. 
This is an important step in the DENV replication cycle, since an acidic pH in the late 
endosome is required for DENV fusion and entry. Although bafilomycin, a specific 
inhibitor of vATPases, has been reported to inhibit flaviviruses in both mammalian and 
insect cells [93,94,101], this is to our knowledge the first functional evidence in adult Ae. 
aegypti for the role of the vATPase complex as a DENV host factor, and it suggests that 
this class of enzyme could be a promising target for chemical interventions, such as the 




The knockdown of a candidate DENV host factor, HMGB gene (AAEL011414), 
unexpectedly resulted in a significant increase in SIN midgut DENV titers, suggesting 
that it may function as a restriction factor instead in this strain. This is in agreement with 
the relatively well-studied role of this gene family in mammalian cells, in which human 
HMGB1 translocates out of the nucleus and is released from DENV-infected epithelial 
and dendritic cells, triggering a pro-inflammatory antiviral response [160-162]. While our 
functional data suggest that Ae. aegypti HMGB may play a similar antiviral role at least 
in the SIN strain, the transcript abundance pattern of this gene across our panel runs 
counter to this possibility. Since HMGB family members are also abundant in the 
nucleus, where they regulate chromatin structure, transcription, and DNA repair and 
replication[163], the transcription pattern we observed may have more to do with one or 
more of these functions than with a response to DENV. A recent study characterizing a 
separate Ae. aegypti HMGB family member (AAEL011380) confirmed that it, like 
human HMGB1, effectively binds and alters the topology of DNA. The authors suggest 
diverse regulatory roles for mosquito HMGB family members, for example in 
vitellogenesis and molting, in addition to innate immunity[164]. This example illustrates 
the idea that the transcriptome is shaped by multiple environmental factors, and it 
underscores the importance of performing functional assays to validate any predictions 
drawn from transcriptomic data. 
High-throughput RNAi screens have proved to be a powerful method for 
identifying candidate flavivirus host and restriction factors in vertebrate and invertebrate 
systems [93]. Our panel of laboratory and field-derived Ae. aegypti strains with a range of 




We tested the Ae. aegypti orthologs of three candidate DENV host factors identified 
through an RNAi screen in Drosophila cells [93] for ability to modulate resistance to 
infection by silencing them in three susceptible mosquito strains. However, only the 
knockdown of a gene encoding an N-acetylglucosa- mine-6-phosphate deacetylase (N-
Gluc, AAEL002430) significantly decreased midgut DENV2 titers, and this effect was 
only seen in the Rock strain and not in the SIN or PTri strains. This result was somewhat 
unexpected, given the strength of these hits in the initial high-throughput RNAi screen 








Molecular characterization of Aedes aegypti ML and 
Niemann-Pick type C family members as dengue virus 
host factors 
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Upon exposure to dengue virus, the Aedes aegypti mosquito vector mounts an 
anti-viral immune defense by activating the Toll, JAK/STAT, and RNAi pathways, 
thereby limiting infection. While these pathways and several other factors have been 
identified as dengue virus antagonists, our knowledge of factors that facilitate dengue 
virus infection is limited. Previous dengue virus infection-responsive transcriptome 
analyses have revealed an increased mRNA abundance of members of the myeloid 
differentiation 2-related lipid recognition protein (ML) and the Niemann Pick-type C1 
(NPC1) families upon dengue virus infection. These genes encode lipid-binding proteins 
that have been shown to play a role in host-pathogen interactions in other organisms. 
RNAi-mediated gene silencing of a ML and a NPC1 gene family member in both 
laboratory strain and field-derived Ae. aegypti mosquitoes resulted in significantly 
elevated resistance to dengue virus in mosquito midguts, suggesting that these genes play 
roles as dengue virus agonists. In addition to their possible roles in virus cell entry and 
replication, gene expression analyses suggested that ML and NPC1 family members also 
facilitate viral infection by modulating the mosquito’s immune competence. Our study 
suggests that the dengue virus influences the expression of these genes to facilitate its 







Through genome-wide transcriptomic analyses, in conjunction with RNAi-
mediated gene silencing, we have identified the Toll and JAK-STAT pathways as key 
DENV antagonists that act by controlling virus restriction factors [12,59,103]. DENV 
infection-responsive transcriptome analyses have revealed that the transcript abundance 
of five members of two lipid-binding protein gene families, the myeloid differentiation 2-
related lipid recognition protein (ML) and Niemann Pick-type C1 (NPC1) families, is 
increased in response to DENV infection. Since DENV is an enveloped virus and its 
outer shell is lipid-based, these lipid-binding proteins are likely to play a role(s) in 
mosquito-virus interactions. 
The ML domain is a lipid recognition protein domain found in several proteins 
with lipid-binding properties [100,157,158]. Members of this family have diverse 
functions associated with lipid recognition, including pathogen recognition, lipid 
trafficking and metabolism, and pheromone perception [98,99,105,106,158,159]. A role 
for the ML domain in immune recognition has been described for the vertebrate MD2 
protein and its insect homologs. MD2 is a secreted glycoprotein that mediates the 
activation of the vertebrate Toll-like receptor 4 (TLR4) upon exposure to bacterial 
lipopolysaccharide (LPS) [101,165,166]. Drosophila MD2 homologs have been shown to 
mediate the activation of the immune deficiency (IMD) immune signaling pathway upon 
exposure to lipopolysaccharide (LPS) [160,167]. The An. gambiae homolog of ML, 
AgMDL1, is involved in the mosquito’s immune defense against Plasmodium falciparum 
infection [103,168]. Niemann-Pick disease type C1 (NPC1) is another class of lipid-




proteins function together with the NPC2 proteins in the late endosomal/lysosomal 
system [12,40,100,158]. NPC1 has been shown to be required for the Ebola virus to 
escape from the vesicular compartment [97,105,106], but the function of the NPC1 
family in DENV infection in mosquito has yet not been investigated.  
Although these lipid-binding protein families have been shown to be involved in 
virus-host interaction and immune responses in various systems, little is known about 
their function in the Ae. aegypti-DENV interaction. Here, we investigated the role of Ae. 
aegypti ML and NPC1 gene family members in modulating DENV infection in the 
mosquito by conducting RNAi-mediated gene silencing and gene expression studies. Our 
results suggest roles for the ML and a NPC1 proteins as agonists of DENV in the 
mosquito. Furthermore, our data suggest that the virus might influence the expression of 
these genes to facilitate its infection, emphasizing the importance of lipid-binding 






MATERIALS AND METHODS  
Bioinformatics analyses and genes selection 
The gene sequences and gene annotations for the insect ML and NPC gene 
families were obtained from the ImmunoDB (http://cegg.unige.ch/Insecta/immunodb) 
and Vectorbase (http://aaegypti.vectorbase.org/) databases [12,165,166]. To compare 
sequence similarity, a multiple sequence alignment (MSA) was generated using t-coffee 
software (http://www.tcoffee.org/) [156,167]. The MSA was then used to generate a 
phylogenetic tree using MEGA 5.05 software [168,169]. ML and NPC genes that 
potentially play a role in DENV infection were suggested from the transcriptional 
changes of these genes in previous microarray-based transcriptome studies [12,40,169], 
Dimopoulos group, unpublished data). 
Mosquito strains and mosquito maintenance 
The mosquitoes used for most of the experiments were of the Ae. aegypti 
Rockefeller/UGAL strain. A second mosquito strain was used to confirm that the results 
were common among different mosquito strains. This strain was a recently colonized Ae. 
aegypti population obtained from the Caribbean island of Saint Kitts (sixth to seventh 
generation) [97]. The mosquitoes were maintained on a 10% sugar solution at 27oC and 
95% humidity with a 12-hr light/dark cycle, following the protocol described previously 
[12].  
Cell culture 
The Ae. albopictus C6/36 cell line was used to propagate DENV. It was 




heat-inactivated FBS, 1% L-glutamine, 1% MEM non-essential amino acids, 10 unit/mL 
penicillin, and 10 µg/mL streptomycin at 32oC and 5% CO2. 
The baby hamster kidney (BHK) cell line was used for plaque assays to determine 
DENV titter. BHK cells were maintained in complete Dulbecco’s modified Eagle’s 
(DMEM) medium supplemented with 10% heat-inactivated FBS, 1% L-glutamine, 10 
unit/mL penicillin, 10 µg/mL streptomycin, and 5 µg/mL plasmocin at 37oC and 5% CO2.  
Genes silencing by RNA interference 
The role of the ML and NPC1 genes in DENV infection in Ae. aegypti was 
assessed using RNA interference-mediated gene silencing as described previously [156]. 
In brief, dsRNAs were constructed using in vitro transcription with the HiScribe™ T7 In 
Vitro Transcription Kit (New England Biolabs). Approximately 200 ng of dsRNA was 
injected into the thorax of cold-anesthetized 3- to 4-day-old female mosquitoes using a 
nano-injector. The dsRNA-injected mosquitoes were kept in the insectary under the 
conditions mentioned above. Gene silencing efficiency, evaluated using real-time PCR, 
was determined by comparison to the GFP dsRNA-injected group at 3 days after dsRNA 
injection, the time when we infected mosquito with DENV. 
DENV propagation and viral infection in the mosquito 
The DENV strain used in these experiments was DENV serotype 2 (New Guinea 
C strain, DENV-2). The virus was propagated in the C6/36 cell line according to a 
protocol previously described [169]. In brief, DENV stock was added to a 75-cm2 flask of 
C6/36 cells at 80% confluence to yield a multiplicity of infection of 1. The virus-infected 
cells were harvested 6 days after infection. The virus was extracted from the cells by 




800g for 10 min, and mixed 1:1 with commercial human blood. The infectious blood 
meal (~106-107 colony-forming units [cfu]/ml) was maintained at 37°C for 30 min prior 
to membrane feeding to 5- to 7-day-old or 3-day post-dsRNA-injected mosquitoes. 
Blood-fed mosquitoes were separated on ice and maintained under the conditions 
mentioned above. 
DENV titration by plaque assay 
Virus titers in the midguts were determined at 7 dpbm according to an established 
protocol [12,169]. Mosquito midguts were dissected in sterile 1XPBS and stored in 
complete DMEM medium at -80°C until used. Midgut samples were homogenized using 
a homogenizer (Bullet Blender, Next Advance) with 0.5-mm glass beads. The virus-
containing homogenates were 10-fold serially diluted in DMEM media, then inoculated 
onto 80% confluent BHK cells in 24-well plates. The cell monolayer was then overlaid 
with 0.8% methylcellulose in complete DMEM medium, and kept for 5–7 days at 37 °C 
and 5% CO2. Plaque forming units (PFUs) were visualized by crystal violet staining. All 
procedures involving DENV-2 infections were carried out in a Biological Safety Level 2 
laboratory. 
Gene expression and silencing efficiency analysis by quantitative PCR 
Gene silencing efficiency and expression of the genes of interest were assayed 
using real-time PCR. Whole mosquito samples were used for the silencing efficiency 
analysis while different mosquito organs were used for gene transcript abundance 
analyses. Mosquito samples were dissected in 1XPBS, collected in RLT buffer 
(QIAGEN), and then stored at -80°C until extraction. Total RNA was extracted from 




were treated with Turbo DNase (Ambion) before reverse transcription with a MMLV 
Reverse Transcriptase kit (Promega) according to the manufacturer’s instructions. The 
cDNA was then used to determine gene expression by quantitative PCR using SYBR® 
Green PCR Master Mix (Applied Biosystem). Transcript abundance of genes was 
compared to the expression of the ribosomal protein gene S7 as a normalization control. 
The primers specific for each gene are presented in Appendix 1. 
Statistical analysis of midgut DENV titer and gene expression level 
The DENV midgut titers of GFP dsRNA and experimental groups were compared 
using the plaque assay results from at least two biological replicates, with the elimination 
of outliers (data outside the median plus 2SD). The significance values were determined 
using either the Kruskal-Wallis test with Dunn’s post-test or the Mann-Whitney test (* 
p<0.05, ** p<0.01).  
 
RESULTS 
ML and NPC1 gene families are distinct and expanded in Ae. aegypti  
The Ae. aegypti genome contains 26 ML-like genes, suggesting an expansion of 
this gene family when compared to other insects (19 in Culex pipiens quinquefasciatus, 
15 in Anopheles gambiae, and 8 in Drosophila melanogaster) (immunoDB database 
(http://cegg.unige.ch/Insecta/immunodb)) [166,170]. Of these 26 members, 24 contain 
the ML domains and are annotated as Niemann-Pick C 2 (NPC2) genes, while the 
remaining two are annotated as Niemann-Pick C1 (NPC1) proteins. However, further 
sequence analysis revealed that the putative NPC1 does not contain the MD2 domain. 




the annotation in immunoDB database). All six cysteine residues are conserved in all the 
ML genes used for analysis, suggesting their importance for protein structure and 
function across organisms. Phylogenetic analysis of the ML genes suggests four groups 
of Ae. aegypti ML genes, with groups 2 being unique to Ae. aegypti (Figure 4.1A). The 
amino acid sequence of AaegML13 is the most conserved when compared to the human 
NPC2 gene. The conserved cholesterol-binding pocket amino acids of the mouse NPC2 
proteins, F66 V96 and Y100 [171], were mutated in some Aedes ML genes (Appendix 4).  
While the human genome contains only one NPC1, the mosquito genomes of C. 
pipiens quinquefasciatus, Ae. gambiae, and Ae. aegypti contain two NPC1 genes (NPC1a 
and NPC1b), as in Drosophila (Figure 4.1B) [172]. The alignment revealed the presence 
of all 13 conserved transmembrane domains and a sterol-sensing domain in NPC1b; in 






Figure 4.1 Phylogenetic tree of the ML and NPC1 gene family in insects. (A) All the 
Ae. aegypti ML family members were compared to all eight D. melanogaster ML genes 
(DmNPC2 A–F), An. gambiae ML1 (AgMDL1), Homo sapiens MD2 (HsMD2), H. 
sapiens NPC2 (HsNPC2), and Mus musculus NPC2 (MmNPC2). (B) The Ae. aegypti 




pipiens quinquefasciatus (Cp), and H. sapiens (Hs). The genes selected for further study 
are indicated by filled circles. 
 
Ae. aegypti ML and NPC1 family members facilitate DENV infection 
Using genome-wide transcriptome analyses, we have previously shown that the 
mRNA abundance of members of the Ae. aegypti NPC1 and ML gene families (3 of 24 
members) were found to be modulated by DENV infection in the mosquito midgut and 
carcass tissue compartments [12,40], suggesting possible roles for these proteins as 
DENV host or restriction factors (data is presented in Appendix3). Upon DENV 
infection, the transcript abundance of AaegML13 and AaegML33 increased in the 
mosquito midgut (2.2 fold) and carcass (2.8 fold), respectively, and the mRNA 
abundance of AaegNPC1b increased in the midgut compartment (1.9 fold). We further 
investigated whether any of these genes is involved in modulating DENV infection in the 
midgut by using RNAi-mediated gene silencing in laboratory Rockefeller/UGAL strain 
Ae. Aegypti, followed by infection with DENV via blood feeding (Figure 4.2). Silencing 
of AaegNPC1b and AaegML33 resulted in a significant reduction in the median DENV 
titer in mosquito midguts by 81.1% and 43.24%, respectively, at 7 dpbm. This result 
suggests that these genes represent potential DENV agonists that could facilitate virus 
infection of the mosquito midgut. The silencing of AaegML13, which is closely related to 
the human ML gene, had no significant effect on midgut DENV infection. The following 
experiments will focus only on the characterization of the AaegNPC1b and AaegML33 





Figure 4.2 Effect of Ae. aegypti ML and NPC1 gene knockdown on midgut DENV 
titers. Members of the ML and NPC1 gene families were silenced in Ae. aegypti 
mosquitoes, and midgut DENV titers at 7 dpbm were determined by plaque assay. Data 
represent a pool of 2–3 biological replicates with the elimination of outliers (data outside 
the median plus 2SD). p-values were determined by comparing the experimental group 
with the dsGFP-treated group in the Mann–Whitney test (*p < 0.05, **p < 0.01). 
 
Functions of AaegNPC1b and AaegML33 as DENV host factors are 
conserved in field-derived strain of Ae. aegypti  
Since the introduction and maintenance of mosquitoes into a laboratory 
environment can impose a selection bias that can lead to genetic differences between 
laboratory-adapted mosquitoes and the natural mosquito population, we investigated 
whether the influence of AaegNPC1b and AaegML33 on DENV infection is conserved in 




strain from Saint Kitts, [97] prior to feeding on DENV-infected blood, resulted in 
significantly lower midgut DENV titers than in the controls, just as we had observed for 
the laboratory strain (Figure 4.3).  
Ae. aegypti NPC1 and ML genes may influence DENV infection through 
the same mechanism or pathway  
Although silencing of some ML and NPC1 genes significantly reduced DENV 
infection in the mosquito midgut, how these genes function as DENV agonists was still 
unknown. To investigate whether these genes were acting as DENV agonists through 
independent mechanisms or the same mechanism/pathway, we compared the effects of 
their independent and combined gene silencing on mosquito susceptibility to virus 
infection. The silencing efficiency of each gene was similar in both single- and double-
silencing experiments (Figure 4.4). The double-silencing of these genes lowered DENV 
infection of the midgut to the same level as did independent silencing of each gene, 
without an apparent synergistic effect (Figure 4.5). This result suggested that these two 
genes influence DENV infection through a similar or same mechanism, as no additive 






Figure 4.3 AaegNPC1b and AaegML33 silencing resulted in lower midgut DENV 
titers in field-derived mosquitoes from Saint Kitts. Data represent a pool of four 
biological replicates with the elimination of outliers (data outside the median plus 2SD). 
p-values were determined by comparing the experimental group with the dsGFP- treated 











Figure 4.4 Silencing efficiency for AaegNPC1b and ML33 in Rock and Kitts strains 
Ae. aegypti. (A) Silencing efficiency in Rockefeller/UGAL strain. (B) Silencing 
























Figure 4.5 Ae. aegypti NPC1b and ML33 may influence DENV infection through the 
same mechanisms. Midgut DENV titers was assayed upon single- and double-silencing 
of AaegNPC1b and AaegML33 at 7 dpbm. Data represent a pool of three biological 
replicates with the elimination of outliers (data outside the median plus 2SD). p-values 
were determined by comparing the experimental group with dsGFP-treated group in the 





AaegNPC1b and AaegML33 may regulate Ae. aegypti immune 
pathways 
Since the transient silencing of AaegNPC1b and AaegML33 resulted in a lower 
midgut DENV level, we wanted to investigate whether this resistance could have resulted 
from altered Toll, Imd, and/or JAK/STAT pathway activity in response to AaegNPC1b 
and AaegML33 gene silencing. Activation of the Toll, Imd, and JAK/STAT pathways 
results in increased antimicrobial peptide (AMP) gene expression [12,59,160]. We 
hypothesized that if AaegNPC1b and AaegML33 play a role in regulating these immune 
pathways (as potential negative regulators), silencing these genes would result in changes 
in the transcript abundance of AMPs and other effector genes. To test this hypothesis, we 
assayed the transcript abundance of AMPs and other effector molecules after silencing 
AaegNPC1b and AaegML33. We measured transcript abundance of immune effector 
genes in the midgut and fat body since they represent major immune tissues and the 
midgut is the first mosquito immune-barrier that the virus encounters [12]. The fat body 
is mainly responsible for humoral and systemic immune responses. Mosquito midguts 
and fat bodies were collected at 1 and 3 days post-dsRNA injection to assay the transcript 
abundance of AMPs and other effector molecules (Figure 4.6). The AMPs analyzed in 
this study were defensin E, cecropin E, lysozyme C, diptericin, and gambicin. Although 
they do not belonging to the AMP class, we also assayed SOCS36E and DVRF1 because 
they are regulated by the anti-dengue JAK/STAT pathway [12,45,59,173] and can be 
used as markers of JAK/STAT activation. The transcript abundance patterns of these 
proteins upon immune pathway activation, as determined by previous studies, are 




Overall, the transcript abundance of several AMP genes was influenced by 
AaegNPC1b and AaegML33 silencing, either in the midgut or fat body, and the 
differential transcript abundances were greater at 3 days than at 1 day post-gene 
silencing. The silencing of AaegNPC1b resulted in an increase in cecropin E and 
lysozyme C transcript abundance, suggesting a possible activation of the Toll pathway, 
since these genes have been shown in previous studies [12] to be induced after Toll 
pathway activation. The up-regulation of DVRF1 transcripts after AaegNPC1b silencing 
also suggested the possible activation of the JAK/STAT pathway [59]. The silencing of 
AaegML33 resulted in an increase in SOCS transcript abundance at 1 day post-dsRNA 
injection, as has been seen for activation of the JAK/STAT pathway [59]. The transcript 
abundance of both SOCS36E and DVRF1 in fat body tissue was decreased at 3 days 
post-silencing of AaegML33 (Figure 4.6D). Defensin E transcripts were enriched in the 
midgut tissue after the silencing of both AaegNPC1b and AaegML33, suggesting an 
activation of the Imd pathway, since this AMP was induced by silencing of the Imd 
pathway negative regulator Caspar [12]. 
 
Table 4.1 Expression pattern of the selected immune genes from previous 
microarray datasets in dengue virus infected midgut (DV MG), dengue virus infected 
carcass (DV Car), Cactus silenced (Toll activated), Caspar silenced (Imd activated), and 
PIAS silenced (JAK/STAT activated). 
Name Accession# DV MG DV Car Cactus Caspar PIAS 
Defensin E AAEL003849  0.824 -0.811 1.697 -0.525 
Diptericin AAEL004833   -0.546   
Cecropin E AAEL000611   1.33  -1.127 
Lysozyme C7B AAEL015404 0.935 1.007 1.105   
Gambicin AAEL004522 1.118 0.851 -1.406 0.85  
SOCS36E AAEL000393  0.909   0.539 






Figure 4.6 Immune-related gene expression changes after AaegNPC1b and 
AaegML33 silencing. Expression of immune-related gene transcripts was assayed by 




tissues. Gene expression levels were assayed from three biological replicates. Error bars 
represent the standard error of the mean (SEM) 
 
Expression patterns and tissue tropisms of AaegNPC1b and AaegML33 
Tissue-specific infection-responsive gene expression patterns can provide 
information about the putative functions of genes during the course of infection. We used 
real-time PCR to compare the transcript abundance of AaegNPC1b and AaegML33 in the 
midgut and fat body. AaegNPC1b was highly expressed almost exclusively in the midgut 
tissue, whereas AaegML33 was expressed at similar levels in both tissues (Figure 4.7).  
 
Figure 4.7 Transcript abundance of AaegNPC1b and AaegML33 in the midgut, and 
fat body in uninfected mosquitos. The graphs show a transcript abundance of 
AaegNPC1b and AaegML33 relative to the transcript abundance of ribosomal S7 gene as 
a normalization control. The data was an average of three pools of 14-day old 
mosquitoes. Transcript abundances were assayed from three biological replicates. Error 
bars represent the standard error of the mean (SEM). 
 
We then investigated the infection-responsive changes in expression of these 
genes by comparing their transcript abundance between DENV-infected and naïve blood-




AaegNPC1b transcript abundance in the midgut was decreased in comparison to 
uninfected controls (a 1.59-fold decrease). The abundance of AaegNPC1b transcripts in 
the midgut increased at 3 dpbm and peaked at 7 dpbm (a 2.15-fold increase), then 
decreased at the later time points (Figure 4.8A). AaegML33 transcripts were enriched in 
the midgut throughout the infection (a 1.99- to 18.85-fold increase) (Figure 4.8B). The 
AaegML33 transcripts in the fat body were also up-regulated at 1, 7, 10, and 14 dpbm 





Figure 4.8 AaegNPC1b and AaegML33 gene expression in the midgut, and fat body 
over the time course of DENV infection. Relative expression of these two genes was 
compared between DENV-bloodfed and naïve-bloodfed mosquitoes. The gene expression 
AaegNPC1b-midgut







































































































was compared relative to the ribosomal S7 gene, and was assayed from three biological 
replicates. Error bars represent the standard error of the mean (SEM). 
 
DISCUSSION 
The ML family comprises of proteins that contain the MD2-related lipid-binding 
(ML) domain, which has been extensively studied in the humansfor its LPS-binding 
property and its role as a TLR4 co-receptor [101]. The immune-related function of the 
ML gene family was recently characterized in the insect model organism, D. 
melanogaster [160]. Three of the eight Drosophila ML genes (DmNPC2a, DmNPC2e, 
and DmNPC2h) were shown to bind to LPS, peptidoglycan, and lipoteichoic acid. Over 
expression of recombinant DmNPC2a and DmNPC2e in the Drosophila S2 cell line 
activates the promoter of the anti-microbial peptide diptericin, which is controlled by the 
IMD immune signaling pathway [160,170]. The An. gambiae ML protein AgMDL1 is 
also implicated in the anti-Plasmodium response [103].  Here we investigated the 
function of the ML and NPC genes in the Ae. aegypti response to DENV infection. Since 
DENV is an enveloped virus, these lipid-binding proteins might be involved in 
interactions with the DENV and modulate immune responses. 
According to the immunoDB database, the Ae. aegypti ML gene family consists 
of 26 members [166]. Our analysis of Ae. aegypti amino acid sequences, however, 
suggested that only 24 genes actually contain the ML domain. The other two ML genes 
reported in the database belong to the Nieman-Pick C1 protein family. This discrepancy 
in annotation might be due to the similar names of NPC1 and NPC2, but in fact, these 
two protein families have different protein structures. NPC2 is a soluble protein 




transmembrane domains, with a sterol-sensing domain located between the third and 
seventh transmembrane domains [158]. Both the NPC1 and NPC2 proteins reside and 
work closely together in the late endosomal/lysosomal compartment of the cells and 
facilitate cholesterol trafficking and metabolism [158,172,174].  
Multiple sequence alignment of the Ae. aegypti ML family revealed variations in 
ML conserved amino acids, as reported for the mouse ML gene [171]. This variation 
implies that the insect ML family, and especially Ae. aegypti, is under high selective 
pressure to expand its spectrum of biological functions and lipid-binding properties. 
According to the phylogenetic analysis, as well as previous classification of the DmNPC2 
[170], Ae. aegypti ML genes can be classified into four different groups. There are eight 
ML genes in group 2 that are unique to Ae. aegypti and lack Drosophila homologs, 
suggesting an expansion of these ML genes during evolution (Figure 4.1A). The 
Drosophila NPC2 a-h genes were grouped as in previous studies, indicating the accuracy 
of the tree [160,170]. The DmNPC2a mutant has been shown to possess physiological 
defects and disordered cholesterol metabolism, similar to that observed with the human 
NPC2 mutant [170,174]. Thus, AaegML13, which clustered together with DmNPC2a and 
human NPC2, may have a similar function, but this relationship was not the focus of our 
study and still needs to be experimentally confirmed. AaegML1 clustered together with 
AgMDL1, an anti-Plasmodium ML gene [103], but its transcript abundance was not 
influenced by DENV infection in any tissue compartment, suggesting that it might not 
play a role in DENV infection. This result is not entirely unexpected, since the mosquito 




The data from previous genome-wide transcriptomic analyses revealed that the 
transcript abundance of several ML genes was influenced by DENV infection in the 
midgut and carcass tissue compartments. The differences in transcript abundance suggest 
that the Ae. aegypti ML genes might have diverse functions in different tissue 
compartments. Functional screening by RNAi-mediated gene silencing of one of the two 
selected ML genes (AaegML33) resulted in lower DENV midgut titers (Figure 4.2), 
suggesting that they facilitate DENV infection, underscoring the potential role of the ML 
gene family members as DENV agonists. AaegML33 was also of particular interest, since 
it belongs to the distinct Ae. aegypti ML group 3, suggesting that it might have a 
specialized DENV-related function in Ae. aegypti.  
Studies of the Drosophila NPC1 gene revealed two NPC1 genes in its genome, 
NPC1a and NPC1b [172,175,176]. All the genomes of insects used for phylogenetic 
analysis also contain two NPC1 genes, suggesting a duplication of the gene to NPC1a 
and NPC1b in a common insect ancestor (Figure 4.1B). NPC1a is an insect NPC1 gene 
more closely related to human NPC1 and is required for molting and sterol homeostasis 
in Drosophila [158,172,174]. NPC1a mutant larvae have abnormally high levels of 
accumulated sterol in cells and are unable to molt [172]. Hence, the Ae. aegypti NPC1a 
might have a similar lipid-related function. The other NPC1 gene, NPC1b, has also been 
studied in Drosophila and found to be involved in sterol absorption in the midgut 
epithelium. The study of DmNPC1a and DmNPC1b revealed that they have non-
redundant roles in sterol homeostasis and are not interchangeable; DmNPC1a is 
important for sterol trafficking, while DmNPC1b is important for sterol absorption [176]. 




are yet to be determined. In Ae. aegypti, the transcript abundance of AaegNPC1 genes 
has been shown to be altered by DENV infection in both midgut and carcass tissue 
compartments, suggesting a possible role for Ae. aegypti NPC1 genes in DENV infection. 
AaegNPC1b was of particular interest to us because it is involved in lipid absorption in 
the midgut and might interact with DENV during that cellular process. The role of NPC1 
as a host factor for virus infection has also been suggested in mammals, since Ebola virus 
can hijack human NPC1 for viral entry into the cytosol [105,106,177]. Silencing of 
AaegNPC1b resulted in lower midgut DENV titers, emphasizing its potential role in 
DENV infection (Figure 4.2).  
 The functions of AaegNPC1b and AaegML33 with regard to DENV infection are 
likely to be conserved across Ae. aegypti strains and populations, since a similar level of 
resistance was observed after silencing of these genes in a strain of recently colonized 
field mosquitoes (Figure 4.3). Simultaneous silencing of AaegNPC1b and AaegML33 
was conducted to provide an indication as to whether these genes might affect DENV 
infection through a similar mechanism, and indeed, we saw comparable levels of 
resistance when they were silenced individually (Figure 4.5).  
Based on the infection data and previous studies of ML genes, we hypothesized 
that AaegNPC1b or AaegML33 could be involved in modulating mosquito immune 
responses to DENV infection. The silencing of these genes resulted in the activation of 
immune pathways, of which the Toll and JAK/STAT pathways are of particular interest, 
since they have been reported to control DENV infection in the mosquito 
[12,45,59,173,178]. To investigate this hypothesis, we measured the expression of 




AaegML33. Our study showed that the transcript abundance of AMPs and other 
JAK/STAT-regulated genes was influenced by AaegNPC1b/AaegML33 silencing, 
suggesting that they playing a role as negative regulators of these anti-DENV innate 
immune pathways (Figure 4.6).  
The expression pattern of the pathway-regulated genes upon AaegNPC1b and 
AaegML33 gene silencing was similar to the pattern obtained when the Toll, Imd, and 
JAK/STAT pathways were activated (Table 4.1) [12,59,176]. We observed an increase of 
SOCS gene transcript abundance, which suggested an activation of the JAK/STAT 
pathway. The dynamic changes in SOCS gene expression likely reflects feedback loops 
in the respective JAK/STAT pathway transcription circuits, as has been shown for the 
Drosophila SOCS36E [31,54]. A prominent up-regulation of defensin E in the midgut 
occurred after the silencing of both AaegNPC1b and AaegML33 (Figure 4.6A and B). 
This increased transcript abundance of defensin E in the midgut suggests that the 
activation of the Imd pathway, or some other unknown immune pathway, might also 
influence DENV infection, as has been shown in Ae. aegypti salivary glands [41,179]. 
Different expression pattern of Defensin E and other immune effector genes in the 
midgut and fat body also suggested that transcription of these genes is controlled 
differently in different mosquito tissues and cell types, as has been shown previously 
[12,59,84,180]. Immune genes can be controlled by multiple immune pathways, and the 
transcriptional regulation by an immune signaling pathway can also be fine-tuned by 
different factors. AaegNPC1b and AaegML33 might serve as alternative regulators of the 
immune signaling pathways. A previous study has shown that DENV can suppress 




[97,177]. Changes in AMP expression after silencing AaegNPC1b and AaegML33 
emphasize their role as immune pathway antagonists, and the up-regulation of the 
AaegNPC1b and AaegML33 by DENV infection is likely reflecting one of the 
mechanisms the virus uses to suppress mosquito immune responses. The function of the 
ML gene as negative regulator was also shown in humans; a splice variance of the MD2 
protein (MD2s) can inhibit TLR4 signaling by competing with normal MD2 for binding 
to TLR4 [12,40,178].  
Tissue-specific transcript abundance analysis revealed that in uninfected 
mosquitoes, AaegML33 was constitutively expressed in the midgut and fat body-
containing carcass (Figure 4.7). In contrast, AaegNPC1b expression was limited mainly 
to the mosquito midgut, which corresponds to the expression of NPC1b in Drosophila 
[97,176], suggesting that the biological role of the NPC1b gene may be conserved among 
insects. The increase in the transcript abundance of the AaegNPC1b and AaegML33 
genes after the ingestion of a DENV-infected blood meal (Figure 4.8) suggests that 
DENV may up-regulate the expression of both genes to prevent immune activation or 
suppress mosquito immune responses. The dynamic temporal changes of their expression 
patterns likely reflect variations in virus titer and propagation of virus infection through 
different host cells and tissues during the course of infection. 
This is the first report to show that two lipid-binding protein families, ML and 
NPC1, play a role as DENV agonists in Ae. aegypti. The silencing of these genes resulted 
in higher resistance to DENV in the mosquito midgut, likely through altered regulation of 
immune pathways. These effects were conserved between laboratory-adapted and field-




expression of these genes to facilitate efficient virus infection. The direct interaction of 
the ML and NPC1 genes with DENV and how these molecules modulate immune 






Conclusion and General Discussion 
Dengue has remained a significant public health concern for a number of decades; 
unfortunately, current dengue controls strategies, such as vector population reduction 
using insecticides, have been shown to be both inefficient and costly, and novel disease 
control strategies are needed to reduce burden of dengue. Dengue transmission-blocking 
through self-propagating genetically-modified mosquitoes has been deemed as a 
logistically simpler and likely cheaper disease control strategy compared to the use of 
vcaccines and drugs that, nevertheless, still under development. However, little is known 
about the interactions between the dengue virus and its insect vector for the development 
of transgenic strategies, and there is therefore a great need for further research in this 
area.  
The recent availability of the Ae. aegypti genome [31,95] together with genomic 
analyses tools, such as Vectorbase [136,179], ave accelerated research on dissecting 
interactions between DENV and mosquito vector. Previous studies identified the Toll, 
JAK/STAT, and RNAi pathways as anti-DENV defense systems in Ae. aegypti 
[12,59,84,139]; however, molecular the mechanisms of how these pathways inhibit 
DENV were still largely unknown. It was also unknown whether these pathways could be 
used for DENV transmission control. To identify and characterize DENV restriction 
factors and host factors in Ae. aegypti, this thesis research has used different approaches 
and tools, such as genetically modified mosquitoes with inducible JAK/STAT pathway 




DENV susceptibility [97], as well as previous microarray-based transcriptomic datasets 
[12,40].  
First we studied the interactions between DENV and Ae. aegypti by using a 
transgenic approach to manipulate the activation of the mosquitoes’ immune pathway, 
specifically the JAK/STAT pathway. We generated transgenic Ae. aegypti 
overexpressing the JAK/STAT pathway components, Dome and Hop, under the control 
of a blood meal-inducible fat body-specific vitellogenin promoter. These genetically 
modified mosquitoes showed an increased resistance to DENV infection, perhaps 
because they had higher expression of dengue virus restriction factors and lower 
expression of DENV host factors than did wild-type mosquitoes. DENV, as RNA virus, 
is prone to mutations which allows the virus to evade control strategies. The multiple 
factors contributing to DENV resistance in our transgenic lines reduce the chance of 
DENV to mutate to overcome the resistance. 
We also showed that these transgenic mosquitoes were useful for studying the 
molecular interactions between DENV and Ae. aegypti. Through transcriptomic 
comparisons by microarray-based methodology together with functional confirmation by 
RNAi, we identified a gene with unknown function (AAEL007703) as a putative DENV 
restriction factor, and the SCP2 and DDX genes as putative DENV host factors.  
This study is the first to provide a proof-of-concept that genetic engineering of the 
mosquitoes’ JAK/STAT immune pathway can be used to render the insect more resistant 
to DENV infection and possibly to block transmission of the disease through further 
development of the technology. Mosquito transgenesis technique has been employed as a 




several countries including Brazil, Panama, Malaysia, and the Cayman islands [181-183]. 
A biotechnology company, Oxitec, has released genetically modified sterile male  Ae. 
aegypti in the field and genetically modified Ae. aegypti carries a lethal gene that 
prevents offsprings of the cross between the genetically modified Ae. aegypti and wild 
mosquitoes to survive to adulthood.  One advantage that a transgenic Ae. aegypti with 
increased DENV resistance has over Oxitec’s technology is that it will not require 
constant production and release of transgenic mosquitoes into the field., but function as a 
logistically simpler and more cost-effective self-propagating system. Offsprings the 
transgenic mosquitoes can survive to adulthood and spread the transgene to next 
generations of mosquitoes through a genetic drive mechanism.  
Our lab has previously established a panel of laboratory and field derived strains 
with various degrees of DENV susceptibility, and transciptomic profiles of these 
mosquitoes suggested that basal level of immune activity might contribute to the 
differences in DENV susceptibility [97]. In this study we confirmed this hypothesis by 
using RNAi-mediated gene silencing to activate or inhibit the Toll, Imd, JAK/STAT, and 
RNAi pathways, and confirm that these pathway contribute to the natural differences in 
DENV susceptibility for different strains to certain degrees. Transciptomic profiles of 
these mosquitoes also showed differential expression of hundreds of genes belongoing to 
various functional groups which play potential roles in DENV infection in Ae. aegypti. 
Hierarchical cluster analyses revealed differential transcript abundance of several DENV 
host and restriction factors among DENV-susceptible and -refractory strains.  Functional 
confirmation by RNAi-mediated gene silencing assays  emphasized an importance of the 




may be a candidate intervention to decrease DENV transmission. The function of 
vATPase genes as a DENV host factor confirmed in this study also support our findings 
from Study 1 that the higher DENV resistance in VgHop mosquitoes might be a result 
from lower expression of vATPase genes. Subsequent experiments by our group applied 
this knowledge in a more translational fashion using a chemical inhibitor of vATPase, 
bafilomycin, to inhibit DENV infection in Ae. aegypti [95].  
Previous studies have shown that DENV perturbs lipid homeostasis [136], and 
have also shown that a lipid carrier protein is important for efficient infection of 
mosquitoes with DENV [139]. This thesis used microarray-based transcriptomic datasets 
of DENV infected Ae. aegypti to identify members of two lipid binding protein families, 
ML and NPC1, that play important roles in DENV infection in Ae. aegypti. Transient 
silencing of NPC1b and ML33 resulted in lower DENV infection in the mosquito midgut, 
suggesting that they were required for efficient infection. We have also shown that the 
silencing of these genes resulted in an induction of AMP gene expression, and DENV 
influenced expression of these genes in a fashion that suggested it would facilitate 
infection. However, the direct interaction between ML and NPC1 genes with DENV and 
how these molecules modulate immune signaling pathways remain to be investigated. 
In recent years, arboviruses other than DENV such as Chikungunya virus and 
Zika virus have also become global public health concerns. However, knowledge of 
interactions between Ae. aegypti and these arboviruses is still limited. It is possible that 
the JAK/STAT pathway is involved in mosquito immunity against these arboviruses 
since the pathway is an evolutionary conserved immune signaling pathway which have 




[184,185]. The VgDome and VgHop transgenic mosquito strains should allow further 
characterization of the role of JAK/STAT pathway in arboviruses infection. Our recently 
colonized and laboratory Ae. aegypti strains can also be used  to study genes that can 
modulate infection of other arboviruses. The natural variations in the basal level of 
immune activity and expression level of host factor genes should allow identification of 
factors contributing to refractoriness against specific arboviruses.  
Collectively, this thesis has used multiple tools available in the lab such as the 
JAK/STAT transgenic mosquitoes, a panel of field-derived and laboratory Ae. aegypti 
strains with various degrees of DENV susceptibility, as well as published microarray 
datasets to broaden our knowledge on the molecular interactions between DENV and Ae. 
aegypti mosquito. We have identified several novel DENV host factors involved in lipid 
trafficking and homeostasis such as SCP2, ML, and NPC1 genes as well as genes that 
facilitate cell entry such as vATPases.  Tools and knowledge generated by this thesis 
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1. Primer sequences 
Chapter 2 
Gene / 
Segment Primer Name Sequence 




Dome1F_PstI TAGTCTGCAGATGGTACAGAGACAAGTATT PstI 
Dome1R_AclI AGCTAACGTTGTTCAGTTCATAGCT AclI 
Dome 
1532-3432 
Dome2F_AclI GAACAACGTTAGCTCGACGTTAAATTTTGC AclI 
Dome2R_PstI TAGTCTGCAGTTACTGCATTTTCAGACCAT PstI 
Hop 1-1516 
Hop1F_EcoRI TATGAGAATTCATGTCGGAGCATGAGAACAAAT EcoRI 
Hop1R_SacI GAAAGAGCTCAGCTCTTGTCCTTTCAAAGA SacI 
Hop 1517-
3408  
Hop2F_SacI AGCTGAGCTCTTTCTGCCGAATAATACCAA SacI 
Hop2R_EcoRI TATGAGAATTCTTAGAAAAGTTGAATTGATT EcoRI 
Trypsin 
terminator 
Tryp-Ter-F TGAATACTAGTTAGGTAGCTGAGCGCATGCGATCTC SpeI 
Tryp-Ter-R TAAGTGCGGCCGCGGCCGGCCGGTCGGCGCGCCCACCCTTGAG NotI, FseI 
AeVg 
promoter 
AeVgPro F TAGTCTCGAGGGCCGGCCGAATTCCACCACCAGG XhoI, FseI 
AeVgPro R TAGTGTCGACCTTCAAGTATCCGGCAGCTG SalI 
Transgenic 




T7FBN13417-F436 TAATACGACTCACTATAGGG ACCCTGGTTCCCGACAAATC dsRNA 
synthesis T7FBN13417-R845 TAATACGACTCACTATAGGG TCCAAAGCATCACGAGCAGT 
qFBN13417-F168 AGCAGTGAACGCAGACATGA realtime 
PCR qFBN13417-R261 GCGATGCGTGATCGTTGTTT 
GAMB 
T7GAMB4522-F58 TAATACGACTCACTATAGGG ACCGATGCTTTGGTGTTTGTT dsRNA 












Segment Primer Name Sequence 
RE sites / 
Notes 
UKN7703 
T7UKN7703-F718 TAATACGACTCACTATAGGG GGTCGGCTATCGGCAGTATC dsRNA 
synthesis T7UKN7703-R1164 TAATACGACTCACTATAGGG CTCCAATCCCAGTTGGCTGT 
qUKN7703-F144 CGCTCGGAACTCGCTATCTT realtime 
PCR qUKN7703-R269 GAATACACACCTCCCGCCAA 
UNK566 
T7UKN566-F135 TAATACGACTCACTATAGGGCAGACCTTCAGACGCTGCTA dsRNA 
synthesis T7UKN566-R413 TAATACGACTCACTATAGGGACGTATGCCTTGCACCAATC 
qUKN566-F5 CGCAGACAATCAAGATAAGCGG realtime 
PCR qUKN566-99 CAGCAACAGAACCCCTAGCA 
DDX 
T7DDX-F272 TAATACGACTCACTATAGGGATGGCCACGAGAACGGATTT dsRNA 
synthesis T7DDX-R480 TAATACGACTCACTATAGGGATCCGTGCCGTTCTCATTGT 
qDDX-F1041 TCGTCTGTTGGACTTCGTCG realtime 
PCR qDDX-R1150 CAACCGATGGCATGAAACCC 
SCP2 
T7SCP2-F71 TAATACGACTCACTATAGGGAGGTTCTGGGAGTGTTCCAGT dsRNA 
synthesis T7SCP2-R233 TAATACGACTCACTATAGGGAAGGTCTTTCCGCTGATGGC 
qSCP2-F22 GAGAGAATCAAGGCTCGCGT realtime 
PCR qSCP2-R107 GCGGTCTTGATGTTCAACTGG 
TEP22 
T7TEP22-87-F2302 TAATACGACTCACTATAGGGTTGGGGGAAATCGCGATCAA dsRNA 
synthesis T7TEP22-87-R2769 TAATACGACTCACTATAGGGGTTCCATTGACCAAACGCCC 
qTEP22-87-F291 TGTCAACGACGGTGGTAGTG realtime 
PCR qTEP22-87-R400 CGCCTGGTTTGTAGACAGGT 
Vitellogen
in 
qAeVg1 F1-6145 TCTTCGGAATTCAGCTCTCTGG realtime 
PCR qAeVg1 R1-6260 ACTGGGCATTCCTTCATGCT 
S7 
qS7-F                          GCAGACCACCATTGAACACA realtime 
PCR qS7-R CACGTCCGGTCAGCTTCTTG 
Dome 
Dome 2F AAACGGTGGCAAAATGAACT realtime 
PCR Dome 2R CTCCAGACCGGTGAGATTGT 
Hop 
Hop 2F CCGGACTTTATCGAGCTGTC realtime 
PCR Hop 2R ATCTGGTTCACTCCGTCGTC 




qDVRF1-R319 TGGGCTGTTCATAGAATGGGG PCR 
GFP 
T7-EGFP-F CGACGATAATACGACTCACTATAGGGTTCATCTGCACCACCGGC dsRNA 
synthesis T7-EGFP-R CGACGATAATACGACTCACTATAGGGCTGGTAGTGGTCGGCGAG 
 
Chapter 3 
Accession no. Primer Name Sequence 
AAEL007768 dsMyD88 F TAATACGACTCACTATAGGGGGCGATT
GGTGGTTGTTATT 
AAEL007768 dsMyD88 R TAATACGACTCACTATAGGGTTGAGCGC
ATTGCTAACATC 
AAEL010083 dsIMD F TAATACGACTCACTATAGGGACCGAAG
AAGACCGCACAAGGC 










AAEL006794 dsDcr2 F TAATACGACTCACTATAGGGGCATTGAC
GACGAAATCATCGTCCGATG 
AAEL006794 dsDcr2 R TAATACGACTCACTATAGGGACCATGG
CATCCGCCGGTGTCTTGTCC 
AAEL011414 dsHMBG F TAATACGACTCACTATAGGGCGCCAAG
CGAGGTGGTGAGC 
AAEL011414 dsHMBG R TAATACGACTCACTATAGGGGTCCTTGC
CGCCGCCATTTC 
AAEL010429 dsAller10-13 F  TAATACGACTCACTATAGGGAGACCAG
CCCCGAGTTCAAGG 
AAEL010429 dsAller10-13 R TAATACGACTCACTATAGGGCCCCAGCC
GAAGAAACCGGC 
AAEL012819 dsvATP-G F TAATACGACTCACTATAGGGAAGGCCG
CCGAAAAGGTCGG 
AAEL012819 dsvATP-G R TAATACGACTCACTATAGGGGTGAGAG
CTGAGGGCCCGGT 
AAEL012092 dsLRRprot F TAATACGACTCACTATAGGGCCTGCCTC
GGTTGGCACTGG 
AAEL012092 dsLRRprot R TAATACGACTCACTATAGGGGACCAGC
TTGCCGGACGTGA 
AAEL015458 dsTsf F TAATACGACTCACTATAGGGTAGGAGG
CGCCCCAGCCAAA 





AAEL002833 dsCatL F  TAATACGACTCACTATAGGGACTGCGG
CTCGTGTTGGTCG 





Accession no. Primer Name Sequence 
AAEL007768 RT MyD88 F GGCGAGGGTTGTTTCAAGTA 
AAEL007768 RT MyD88 R TCCCATCTGTCGATTAAGCC 
AAEL010083 RT IMD F TCATTCCGCGAAGGGCTGGC 
AAEL010083 RT IMD R AGCGCAGAAACATCGTTCGCA 
AAEL012471 
 




RT Dome 2R 
CTCCAGACCGGTGAGATTGT 
AAEL006794 RT Dcr2 F CAATTGCTACCGTTGGGAGT 
AAEL006794 RT Dcr2 R ATTGATCCCCCAAAAAGACC 
AAEL011414 RT HMBG F CTGTGGCTCAACTCTGCCCGC 
AAEL011414 RT HMBG R AGCTCACCACCTCGCTTGGC 
AAEL010429 RT Aller10-13 
2F  
ACGAAACGGTTGCTTTATTGCCTCT 
AAEL010429 RT Aller10-13 
2R 
GCCATCCACATCGAGTCCGTAGC 
AAEL012819 RT vATP-G F CAGCTGCTGGCCGCTGAGAA 
AAEL012819 RT vATP-G R TTTAGACGGCGGGCCTTGCG 
AAEL012092 RT LRRprot F CCGGAGGTACCGAGAGCCCA 
AAEL012092 RT LRRprot R TCGTCCCCTAGCGGCTTCCA 
AAEL015458 RT Tsf F TCGTGATGTCCGTCCGGCCT 
AAEL015458 RT Tsf R CGCTGGTGGATGTTGCGGGT 
AAEL002833 RT CatL F  TGGAGCGACCGACAAGGGCT 
AAEL002833 RT CatL R CCCCAGGTGGTTCCCCACGA 
AAEL009496 RT S7 F GCAGACCACCATTGAACACA 
























qAeSOCS36E F1-81 CCACTGTTTGGTGCCGGATTTGC 




DVRF1 DVRF1-F TCTTCATGCGGCATACTCAG DVRF1-R AGGAATGTTTCCGAGGGTTT 
LYSC7B LYSC-F CCACGGCAACTGGATATGTCT LYSC-R TCTGCGTCACCTTGGTGGTAT 
Cecropin E CecE-F CGAAGCCGGTGGTCTGAAG CecE-R ACTACGGGAAGTGCTTTCTCA 









2. Log2-fold values and functional groups of transcripts that were up- 
or down-regulated in the fat body of VgDome or VgHop lines relative to 
WT 
 
Gene ID Description Functional group VgDome VgHop 
AAEL001904 arp2/3 CS 
 
-0.773 
AAEL002185 cuticle protein, putative CS -0.61 -0.853 
AAEL002495 
conserved hypothetical protein 
(mucin-like protein) CS 
 
-1.65 




conserved hypothetical protein 
(mucin-like protein) CS 0.65 -1.569 
AAEL005417 annexin x CS 0.194 0.964 
AAEL010094 cyclin b CS 0.505 -1.224 
AAEL013984 structural constituent of cuticle CS 0.389 -1.924 
AAEL005146 conserved hypothetical protein CS -1.023 -0.652 
AAEL005426 annexin x CS -1.442 -0.606 
AAEL012644 conserved hypothetical protein CS 2.702 
 
AAEL017334 
Conserved hypothetical protein 
(chitin-binding domain type 2) CS 2.267 
 AAEL000335 lamin CS -0.971 -0.84 
AAEL006726 innexin CS -1.513 -0.835 
AAEL009572 cyclin B3 CS -0.784 -0.818 




Odorant-binding protein 99c, 
putative CSR 1.051 0.893 
AAEL000005 hypothetical protein D 
 
-0.76 
AAEL000079 hypothetical protein D 
 
-0.769 
AAEL000105 beta-alanine synthase, putative D 0.322 -1.513 
AAEL000115 conserved hypothetical protein D 
 
0.864 




single-stranded DNA binding 
protein, putative D 
 
-0.903 
AAEL000159 nipsnap D 0.715 1.073 
AAEL000262 conserved hypothetical protein D 
 
-0.848 




hypothetical protein (pacifastin 
light chain [Culex 
quinquefasciatus]) D -0.516 -1.886 
AAEL000807 
Tetratricopeptide repeat 
protein, putative D -0.165 0.829 




Gene ID Description Functional group VgDome VgHop 
AAEL001087 synaptic vesicle protein D 0.724 1.109 
AAEL001100 phosphoserine phosphatase D 0.417 1.23 
AAEL001287 conserved hypothetical protein D 
 
0.861 
AAEL001293 conserved hypothetical protein D -0.214 1.057 
AAEL001307 SEC14, putative D 
 
1.183 
AAEL001352 scaffold attachment factor b D -0.575 -0.803 








AAEL001795 orfY, putative D 0.615 0.818 
AAEL002048 histidyl-tRNA synthetase D 0.337 0.969 
AAEL002125 conserved hypothetical protein D 
 
-0.762 
AAEL002194 uricase D -0.48 -1.086 
AAEL002261 GTP cyclohydrolase i D 
 
0.968 
AAEL002501 protein disulfide isomerase D 
 
2.191 








AAEL002920 hypothetical protein D 
 
-1.949 




nonsense-mediated mrna decay 
protein D -0.355 1.211 




low molecular weight protein-
tyrosine-phosphatase D 0.221 1.078 
AAEL003179 
protein arginine n-
methyltransferase 1, putative D 
 
-0.857 








AAEL003413 f-spondin D 
 
1.129 
AAEL003509 smap1 D -0.37 -0.805 
AAEL003581 
amidophosphoribosyltransferas
e D -0.447 0.803 
AAEL003599 
DNA binding, sulfiredoxin 




purine biosynthesis protein 6, 
pur6 D -0.542 2.35 












vacuolar protein sorting 18 
(deep orange protein) D -0.385 1.032 




secreted ferritin G subunit 










HIG1 domain family member 




cell division cycle 20 (cdc20) 
(fizzy) D 0.248 1.017 
AAEL004503 conserved hypothetical protein D 0.3 1.134 
AAEL004547 conserved hypothetical protein D -0.355 0.937 
AAEL004566 myo inositol monophosphatase D 
 
-1.415 





beta chain D 0.674 1.109 






AAEL005199 hypothetical protein D 0.607 1.41 





idine synthase, putative D 0.475 2.203 
AAEL005457 conserved hypothetical protein D -0.656 0.937 
AAEL005558 conserved hypothetical protein D -0.184 1.717 
AAEL005760 hypothetical protein D 0.037 1.508 
AAEL006023 
Vanin-like protein 1 precursor, 
putative D -0.541 -0.98 
AAEL006279 hypothetical protein D 
 
-0.955 
AAEL006446 trehalose-6-phosphate synthase D -0.398 -0.862 
AAEL006518 cytidine deaminase, putative D 
 
-2.892 
AAEL006544 nucleoporin P54 D 
 
-1.09 
AAEL006602 hypothetical protein D 0.467 0.752 
AAEL006712 serine/threonine protein kinase D -0.662 -0.897 
AAEL006909 hypothetical protein D 
 
-0.928 






Gene ID Description Functional group VgDome VgHop 
AAEL007114 conserved hypothetical protein D -0.566 -0.79 




secreted ferritin G subunit 
precursor, putative D -0.388 -0.768 
AAEL007621 conserved hypothetical protein D 
 
2.049 
AAEL007686 conserved hypothetical protein D 
 
0.755 
AAEL007701 conserved hypothetical protein D 
 
-0.85 
AAEL007767 conserved hypothetical protein D -0.624 0.977 
AAEL007783 centromere protein-A, putative D -0.437 -1.078 
AAEL007828 palmitoyl-protein thioesterase D 
 
2.194 
AAEL008007 conserved hypothetical protein D 0.391 0.955 








AAEL008753 conserved hypothetical protein D 0.331 -1.126 
AAEL008863 
protein regulator of cytokinesis 
1 prc1 D 
 
-1.226 




GTP-binding protein (i) alpha 
subunit, gnai D -0.553 -0.792 
AAEL009309 lipid depleted protein D 0.207 1.381 
AAEL009508 zinc finger protein D 
 
-0.852 
AAEL009629 endoU protein, putative D 0.452 -0.818 
AAEL009636 conserved hypothetical protein D 
 
0.876 




arsenite inducuble RNA 
associated protein aip-1 D -0.473 1.379 
AAEL009968 hypothetical protein D 
 
-0.987 





dehydrogenase D -0.661 -1.28 
AAEL010280 conserved hypothetical protein D 0.666 0.874 
AAEL010455 cxyorf1 D 
 
-0.827 
AAEL010520 conserved hypothetical protein D 0.17 -0.778 
AAEL010572 
late endosomal/lysosomal MP1 
interacting protein, putative D 
 
-1.297 
AAEL010656 conserved hypothetical protein D 
 
1.414 
AAEL010879 conserved hypothetical protein D 0.484 -1.093 
AAEL011063 
tumor endothelial marker 7 
precursor D 0.567 0.817 




Gene ID Description Functional group VgDome VgHop 
AAEL011135 conserved hypothetical protein D 
 
-0.774 




GTP-binding protein (i) alpha 
subunit, gnai D -0.181 -0.75 




late endosomal/lysosomal MP1 
interacting protein, putative D 
 
-1.047 
AAEL011580 conserved hypothetical protein D 
 
0.786 
AAEL011853 conserved hypothetical protein D -0.376 -0.865 
AAEL011892 
receptor for activated C kinase, 
putative D -0.497 -1.134 
AAEL011980 hypothetical protein D -0.594 -0.84 
AAEL012233 hypothetical protein D 
 
1.117 





aminotransferase D -0.743 1.099 
AAEL012502 conserved hypothetical protein D 0.108 -1.179 
AAEL012856 hypothetical protein D 
 
1.083 
AAEL013078 glycosyltransferase D 0.595 0.764 
AAEL013334 conserved hypothetical protein D 0.192 1.068 
AAEL013338 
lethal(2)essential for life 
protein, l2efl D 
 
-0.949 





regulatory subunit D 
 
-0.957 










sulfurase (mosc) D 0.428 0.787 
AAEL014310 hypothetical protein D 
 
-0.852 
AAEL014561 conserved hypothetical protein D -0.189 1.955 
AAEL015375 serine/threonine protein kinase D 
 
-0.905 
AAEL015658 conserved hypothetical protein D 
 
-1.281 
AAEL000016 conserved hypothetical protein D 1.064 0.748 
AAEL000315 pigeon protein (linotte protein) D 0.838 
 AAEL000442 conserved hypothetical protein D -0.931 -0.656 
AAEL000776 conserved hypothetical protein D -0.846 
 AAEL000973 conserved hypothetical protein D -0.789 -0.431 
AAEL001666 
nucleic acid binding, zinc ion 




Gene ID Description Functional group VgDome VgHop 
AAEL001682 
nuclear movement protein 
nudc D 1.58 0.221 
AAEL002473 hypothetical protein D -0.777 -0.633 
AAEL002559 conserved hypothetical protein D 1.526 -0.335 
AAEL003213 guanine deaminase D 0.813 0.527 
AAEL003237 
low molecular weight protein-
tyrosine-phosphatase D 0.958 0.295 
AAEL003345 argininosuccinate lyase D -1.081 -0.382 
AAEL003385 conserved hypothetical protein D -0.914 
 AAEL003877 ubiquitin D -0.916 -0.582 
AAEL004860 acireductone dioxygenase D 1.969 
 AAEL005348 hypothetical protein D -0.928 





putative D 1.025 
 AAEL006353 sulfotransferase (sult) D 1.528 0.18 
AAEL006972 
hepatocellular carcinoma-
associated antigen D 1.463 0.23 




E2 i D -0.967 -0.585 
AAEL007702 chaperonin D -0.868 -0.201 
AAEL008076 PIWI D -2.045 
 AAEL008598 conserved hypothetical protein D 1.055 
 AAEL009652 activin receptor type ii D 0.955 
 AAEL009654 hypothetical protein D -1.179 -0.669 
AAEL009859 nucleolar GTP-binding protein D -1.567 
 
AAEL010065 
protein disulfide-isomerase A6 
precursor D 2.233 
 AAEL010943 conserved hypothetical protein D -0.772 0.358 




binding protein D 1.128 -0.242 
AAEL011448 conserved hypothetical protein D 1.044 
 AAEL011452 conserved hypothetical protein D 0.913 
 AAEL011478 cytoplasmic dynein light chain D -0.928 -0.489 
AAEL011849 hypothetical protein D -0.79 -0.598 
AAEL012260 wdpeat protein D 1.298 -0.709 









decarboxylase, putative D -1.029 
 AAEL013510 smaug protein D -0.972 
 
AAEL013844 
diazepam binding inhibitor, 
putative D 1.276 -0.564 
AAEL014715 
67 kDa polymerase-associated 
factor PAF67, putative D 0.883 0.661 




uridylyltransferase D 1.168 1.245 
AAEL001667 multicopper oxidase D 1.553 1.086 
AAEL002554 anosmin, putative D -1.466 -1.099 
AAEL002860 conserved hypothetical protein D 2.016 1.633 
AAEL005308 pyruvate dehydrogenase D 0.933 1.36 
AAEL005458 carnitine o-acyltransferase D -0.783 0.776 
AAEL006625 conserved hypothetical protein D -1.063 2.651 
AAEL006662 hypothetical protein D 1.212 2.29 
AAEL007484 protein transport protein sec23 D 0.809 -0.805 
AAEL007494 calcineurin b subunit D 0.771 0.791 
AAEL007557 asparagine synthetase D 1.038 1.431 
AAEL007868 
ubiquinol-cytochrome c 
reductase complex 14 kd 
protein D 0.816 1.358 
AAEL008431 a kinase anchor protein D -1.011 -0.919 
AAEL008595 conserved hypothetical protein D -1.162 -0.953 
AAEL008789 apolipophorin-III, putative D -0.792 0.865 
AAEL009962 hypothetical protein D -1.241 -0.96 
AAEL010097 nuclein acid binding D -1.149 -1.591 
AAEL011881 conserved hypothetical protein D 0.897 0.867 
AAEL012605 conserved hypothetical protein D 2.008 1.699 
AAEL012851 wdpeat protein D 0.903 1.017 
AAEL012855 hypothetical protein D 1.019 3.375 
AAEL013851 
conserved hypothetical protein 
(acetyltransferase (GNAT) 
family domain) D 1.233 2.448 
AAEL015631 asparagine synthetase D 1.071 1.418 










Gene ID Description Functional group VgDome VgHop 
AAEL006121 Trypsin, putative DIG 
 
-0.788 
AAEL008080 trypsin-eta, putative DIG 1.369 
 AAEL013262 conserved hypothetical protein DIG -1.001 




enzyme (DCE) isoenzyme, 
putative I 0.357 0.764 
AAEL000087 macroglobulin/complement I 0.414 0.752 
AAEL000621 antibacterial peptide, putative I 
 
1.547 
AAEL000625 antibacterial peptide, putative I 
 
1.659 
AAEL002276 serine protease, putative I -0.461 -1.607 
AAEL002592 hypothetical protein I -0.523 -0.792 
AAEL003625 
clip-domain serine protease, 
putative I 0.452 0.892 
AAEL003723 lysozyme P, putative I 0.691 0.94 
AAEL003832 conserved hypothetical protein I 
 
1.168 
AAEL003841 conserved hypothetical protein I 
 
1.435 
AAEL004401 peroxinectin I 
 
-0.836 




clip-domain serine protease, 
putative I 0.495 -1.312 
AAEL006168 
serine carboxypeptidase, 
putative I -0.372 -0.822 
AAEL007006 serine protease I 0.7 0.834 
AAEL007969 serine protease I 0.665 0.789 
AAEL008607 tep3 I 0.43 -1.084 
AAEL009637 cathepsin b I -0.462 1.513 
AAEL009642 cathepsin b I -0.371 1.828 
AAEL011446 
galactose-specific C-type 
lectin, putative I -0.433 1.316 
AAEL012092 leucinech repeat I 0.601 1.094 
AAEL012251 
low-density lipoprotein 
receptor (ldl) I -0.371 -0.805 
AAEL012471 








aromatic amino acid 
decarboxylase I -0.15 -0.795 
AAEL014349 serine protease I -0.357 -1.681 
AAEL014755 tep2 I 0.07 -0.957 




Gene ID Description Functional group VgDome VgHop 
AAEL017325 
Clip-Domain Serine Protease, 
family B. (Truncated Protease). 
[Source:Aedes_ManualAnnotat
ion;Acc:AAEL800831] I -0.095 -0.978 
AAEL000030 
clip-domain serine protease, 
putative I 1.079 0.496 
AAEL000598 antibacterial peptide, putative I -0.877 0.719 
AAEL000611 antibacterial peptide, putative I -1.488 
 
AAEL003279 
clip-domain serine protease, 
putative I 0.953 0.686 
AAEL004120 
Niemann-Pick Type C-2, 
putative I 0.832 -0.144 
AAEL006434 serine protease, putative I 0.803 -0.39 
AAEL006586 serine protease I -0.976 -0.482 
AAEL007599 cathepsin b I 1.229 0.703 
AAEL011616 serine protease, putative I -0.956 -0.501 
AAEL012064 
Niemann-Pick Type C-2, 
putative I 0.808 0.241 
AAEL014004 
clip-domain serine protease, 
putative I -0.761 0.461 
AAEL014385 conserved hypothetical protein I -1.179 -0.298 
AAEL017536 
Holotricin, Glycine Rich 
Repreat Protein (GRRP), Anti-
Microbial Peptide. 
[Source:Aedes_ManualAnnotat
ion;Acc:AAEL800434] I 0.801 0.186 
AAEL005482 conserved hypothetical protein I 2.369 2.205 
AAEL006271 superoxide dismutase I -0.853 -0.821 
AAEL006704 fibrinogen and fibronectin I 0.794 1.227 
AAEL006830 yellow protein precursor I -0.839 1.7 
AAEL007585 cathepsin b I -0.853 1.184 
AAEL011400 conserved hypothetical protein I 2.634 2.21 
AAEL011610 
galactose-specific C-type 
lectin, putative I 0.767 0.796 
AAEL012216 cathepsin b I -0.776 1.181 
AAEL013417 fibrinogen and fibronectin I 1.584 1.708 
AAEL014390 
galactose-specific C-type 
lectin, putative I 0.76 0.763 
AAEL015312 cathepsin b I 1.105 0.823 
AAEL015458 transferrin I 0.874 2.292 




Gene ID Description Functional group VgDome VgHop 
AAEL017132 
C-Type Lysozyme (Lys-C). 
[Source:Aedes_ManualAnnotat
ion;Acc:AAEL800171] I 1.146 -1.13 
AAEL010125 
mitotic protein phosphatase 1 
regulator, putative I(LRR) -0.382 -1.094 
AAEL000006 
phosphoenolpyruvate 
carboxykinase M 0.511 1.422 








AAEL000101 AMP dependent coa ligase M 
 
1.032 
AAEL000111 nitrilase, putative M 
 
0.928 
AAEL001423 acid phosphatase-1 M 0.676 0.76 
AAEL001586 
glucosyl/glucuronosyl 






AAEL002304 porphobilinogen synthase M 
 
-0.816 
AAEL002964 brain chitinase and chia M -0.248 1.046 
AAEL004059 cystathionine beta-lyase M 
 
0.769 
AAEL004126 sterol desaturase M 0.548 1.252 
AAEL004127 acyl-coa dehydrogenase M 0.656 1 
AAEL004313 fk506-binding protein M -0.434 1.016 
AAEL004739 acyl-coa dehydrogenase M -0.486 1.391 
AAEL004757 
cleavage and polyadenylation 
specificity factor M -0.518 0.768 
AAEL005732 acyl-coa dehydrogenase M 
 
1.331 





dehydrogenase M -0.108 0.758 
AAEL006171 n-myc downstream regulated M 
 
0.786 
AAEL006354 epoxide hydrolase M 
 
-0.851 
AAEL007201 glutamyl aminopeptidase M 
 
-0.888 
AAEL007707 malate dehydrogenase M 
 
-1.012 
AAEL007880 ornithine decarboxylase M -0.091 -0.782 
AAEL008006 
3-hydroxyacyl-coa 












Gene ID Description Functional group VgDome VgHop 
AAEL009503 4-nitrophenylphosphatase M 0.686 1.389 
AAEL009911 rotamase M 0.38 1.465 
AAEL010366 
glucosyl/glucuronosyl 
transferases M 0.592 0.918 





reductase small chain M 
 
-0.945 
AAEL010938 l-asparaginase M 
 
0.842 
AAEL011126 alcohol dehydrogenase M 
 
-0.794 





(pa2g4/ebp1) M -0.613 0.841 
AAEL012341 lysosomal acid lipase, putative M -0.557 -1.067 
AAEL012430 AMP dependent ligase M -0.509 -1.048 
AAEL012697 




AAEL013245 proacrosin, putative M 0.574 1.485 
AAEL013458 
glutamine synthetase 1, 2 
(glutamate-amonia ligase) (gs) M -0.11 -2.122 




Conserved hypothetical protein 
(alcohol dehydrogenase 2 
[Culex quinquefasciatus] _ M -0.364 1.013 
AAEL017299 




AAEL007097 4-nitrophenylphosphatase M -1.064 -0.357 
AAEL007883 fk506-binding protein M 0.798 
 AAEL008144 AMP dependent ligase M 0.918 -0.327 




putative M -1.184 -0.387 
AAEL009462 
hydroxyacylglutathione 
hydrolase M 1.342 0.13 




phosphorylase M 0.834 0.444 
AAEL012825 
bifunctional purine 
biosynthesis protein M -1.089 









Gene ID Description Functional group VgDome VgHop 
AAEL015143 
glycine rich RNA binding 




transferases M 0.975 1.273 
AAEL002422 
cytoplasmic polyadenylation 
element binding protein (cpeb) M -1.192 -0.861 
AAEL009246 glycoside  hydrolases M 0.878 1.662 
AAEL014709 methionine-tRNA synthetase M -1.072 2.089 
AAEL015337 
neutral alpha-glucosidase ab 
precursor (glucosidase ii alpha 
subunit) (alpha glucosidase 2) M -0.967 -2.407 









AAEL008862 conserved hypothetical protein PROT -0.523 -1.014 
AAEL009771 hypothetical protein PROT 
 
0.816 
AAEL014350 hypothetical protein PROT 
 
-0.83 
AAEL014353 conserved hypothetical protein PROT 
 
-0.957 














carboxypeptidase PROT 1.067 0.403 
AAEL015432 Trypsin, putative PROT -1.16 -0.491 
AAEL000252 hypothetical protein PROT 0.845 0.766 




carboxypeptidase PROT 0.932 1.054 
AAEL010196 trypsin PROT 2.031 2.224 
AAEL010634 hypothetical protein REDOX -0.295 0.938 
AAEL010592 esterase, putative REDOX 1.749 0.442 
AAEL000546 carboxylesterase RSM 
 
-1.14 
AAEL001960 cytochrome P450 RSM 
 
-1.033 
AAEL002046 cytochrome P450 RSM -0.741 -0.82 




Gene ID Description Functional group VgDome VgHop 





protein L1 RSM -0.644 -0.805 
AAEL005178 juvenile hormone esterase RSM 0.616 1.172 





oxidoreductase subunit B14.5b RSM -0.268 0.956 
AAEL006230 
gonadotropin inducible 
transcription factor RSM 
 
-0.758 
AAEL006824 cytochrome P450 RSM -0.314 2.468 
AAEL007046 
mitochondrial brown fat 
uncoupling protein RSM 0.193 -0.854 
AAEL007355 
mitochondrial ribosomal 
protein, S18A, putative RSM 0.258 0.95 
AAEL008128 
mitochondrial inner membrane 
protein translocase, 13kD-
subunit, putative RSM 0.426 0.781 
AAEL008397 glutathione peroxidase RSM 
 
-1.617 
AAEL010075 oxidoreductase RSM 
 
1.014 




oxidation reduction RSM 
 
-0.863 
AAEL013066 checkpoint kinase RSM -0.473 -1.071 
AAEL013555 cytochrome P450 RSM -0.246 1.358 





dehydrogenase, putative RSM 
 
1.103 
AAEL014830 cytochrome P450 RSM 
 
1.882 
AAEL015578 alpha-esterase RSM 0.108 -1.038 






putative RSM 1.049 0.578 
AAEL002683 aldehyde oxidase RSM 1.058 
 AAEL003890 cytochrome P450 RSM -1.064 -0.396 
AAEL007752 
cytochrome c oxidase, subunit 
VIIA, putative RSM 1.135 -0.688 
AAEL008757 juvenile hormone esterase RSM 0.861 0.392 
AAEL009225 
mitochondrial ribosome 




Gene ID Description Functional group VgDome VgHop 
AAEL012845 
mitochondrial import inner 
membrane translocase subunit 




dehydrogenase, putative RSM -1.282 




protein, S10, putative RSM 1.038 0.216 
AAEL000986 
NADH-ubiquinone 
oxidoreductase ashi subunit RSM 2.027 2.067 
AAEL003423 
NADH dehydrogenase, 
putative RSM 1.189 -1.074 
AAEL004450 cytochrome b5, putative RSM 0.84 0.826 
AAEL007946 
glutathione-s-transferase theta, 
gst RSM 0.919 -0.797 
AAEL010181 
mitochondrial ribosomal 
protein, L51, putative RSM 1.064 0.868 
AAEL000032 ribosomal protein S6 RTT 0.606 0.965 
AAEL000497 histone h2a RTT 0.678 -1.106 





ribonucleoprotein r RTT -0.27 0.895 
AAEL003352 ribosomal protein l7ae RTT 0.534 0.751 
AAEL003427 ribosomal protein S9, putative RTT -0.559 -0.751 
AAEL003646 conserved hypothetical protein RTT 
 
0.867 
AAEL003685 histone H3 RTT 0.449 -1.192 
AAEL003818 histone h2a RTT 
 
-1.202 
AAEL003820 histone h2a RTT 
 
-1.126 
AAEL003826 histone h2a RTT 
 
-1.197 




60S ribosomal protein L44 




DEAD box ATP-dependent 
RNA helicase RTT -0.699 -0.79 
AAEL005368 





eukaryotic translation initiation 
factor 3, theta subunit RTT 0.186 1.249 
AAEL007928 
eukaryotic translation initiation 
factor 4 gamma RTT 
 
-0.827 
AAEL008266 hypothetical protein RTT 
 
-0.847 






Gene ID Description Functional group VgDome VgHop 
RNA helicase 




DNA polymerase epsilon 




DEAD box ATP-dependent 
RNA helicase RTT -0.278 1.474 
AAEL011150 
RNA-binding protein 




ribosome biogenesis regulatory 
protein RTT 0.619 1.255 
AAEL012684 conserved hypothetical protein RTT 0.006 1.378 
AAEL012877 
homeobox protein 
extradenticle, putative RTT 0.126 0.978 
AAEL013221 60S ribosomal protein L10a RTT 0.505 1.023 
AAEL014764 
acidic ribosomal protein P1, 
putative RTT -0.184 0.929 
AAEL014838 60S ribosomal protein L27e RTT -0.444 -0.751 
AAEL017595 
5S ribosomal RNA [Source: 




5S ribosomal RNA [Source: 




5S ribosomal RNA [Source: 
RFAM 9.0] RTT 0.435 0.757 
AAEL002534 60S ribosomal protein L10 RTT -2.644 0.277 
AAEL003071 
tRNA pseudouridine synthase 
D RTT 0.986 0.527 
AAEL003396 60S ribosomal protein L32 RTT -0.765 
 AAEL005127 ribonuclease UK114, putative RTT 0.872 0.448 
AAEL006698 60S ribosomal protein L31 RTT 0.812 0.431 
AAEL007005 histone h2a RTT 0.795 
 
AAEL010821 
60S acidic ribosomal protein 
P0 RTT 1.649 -0.269 
AAEL011251 RNA binding motif protein RTT -0.934 -0.681 
AAEL012074 conserved hypothetical protein RTT 2.387 0.194 
AAEL013964 ribosomal protein L20, putative RTT 1.411 
 AAEL014106 ATP-dependent RNA helicase RTT -0.763 -0.358 
AAEL015244 splicing factor 3a RTT 1.212 
 
AAEL017685 
Nuclear RNase P [Source: 
RFAM 9.0] RTT 1.164 0.367 
AAEL000518 histone h2a RTT 0.826 -1.071 
AAEL000525 histone h2a RTT 0.768 -0.969 




Gene ID Description Functional group VgDome VgHop 
AAEL005129 40S ribosomal protein S30 RTT 0.859 2.634 
AAEL011447 60S ribosomal protein L14 RTT 1.526 1.235 
AAEL012686 ribosomal protein S12, putative RTT 1.388 1.085 
AAEL017742 
5S ribosomal RNA [Source: 
RFAM 9.0] RTT 0.846 0.766 
AAEL017760 
5S ribosomal RNA [Source: 
RFAM 9.0] RTT 0.888 0.76 





containing protein TRP -0.269 1.065 
AAEL002063 cationic amino acid transporter TRP 0.565 0.984 
AAEL002576 sodium/solute symporter TRP 
 
0.931 
AAEL003548 sulfate transporter TRP -0.641 -0.859 
AAEL003626 
sodium/shloride dependent 




Sialin, Sodium/sialic acid 
cotransporter, putative TRP 
 
-0.758 
AAEL005769 glucose dehydrogenase TRP 
 
-0.836 
AAEL006138 hypothetical protein TRP 
 
1.353 
AAEL008406 cationic amino acid transporter TRP 0.647 0.955 
AAEL008635 abc transporter TRP -0.293 0.907 
AAEL009832 exocyst complex protein exo70 TRP -0.255 -1.481 
AAEL010102 tetraspanin, putative TRP 
 
1.164 
AAEL010434 conserved hypothetical protein TRP 
 
1.519 
AAEL010481 sugar transporter TRP -0.343 -1.701 





lectin TRP 0.18 -0.972 
AAEL011025 










AAEL015549 calcineurin b subunit TRP 0.387 0.769 
AAEL002555 sodium/solute symporter TRP 0.771 
 AAEL002726 D7 protein, putative TRP -0.869 
 AAEL004855 adp,atp carrier protein TRP -0.778 -0.628 
AAEL005496 zinc/iron transporter TRP 0.884 0.703 
AAEL012674 d-amino acid oxidase TRP 1.387 
 AAEL007458 amino acid transporter TRP -0.833 -0.945 




Gene ID Description Functional group VgDome VgHop 
cotransporter, putative 
AAEL000309 hypothetical protein U 0.318 -1.223 
AAEL000619 conserved hypothetical protein U 
 
1.291 
AAEL001325 conserved hypothetical protein U 0.188 -1.639 
AAEL001414 conserved hypothetical protein U -0.064 0.884 
AAEL001718 conserved hypothetical protein U 0.397 0.776 
AAEL001880 conserved hypothetical protein U 
 
1.242 
AAEL001885 conserved hypothetical protein U 
 
1.258 
AAEL001888 hypothetical protein U 0.555 1.118 
AAEL001892 conserved hypothetical protein U -0.484 -1.661 
AAEL001897 conserved hypothetical protein U -0.323 -1.378 
AAEL002719 conserved hypothetical protein U 0.362 0.81 
AAEL002758 conserved hypothetical protein U 0.286 1.46 
AAEL002815 conserved hypothetical protein U 
 
1.197 
AAEL002828 hypothetical protein U 
 
-0.805 
AAEL002900 conserved hypothetical protein U 
 
0.774 
AAEL003029 hypothetical protein U -0.316 0.81 
AAEL003067 conserved hypothetical protein U 0.11 0.997 
AAEL003766 hypothetical protein U -0.211 0.901 
AAEL003842 hypothetical protein U 0.267 0.838 
AAEL003944 conserved hypothetical protein U 
 
1.086 
AAEL004498 hypothetical protein U 0.384 0.806 
AAEL004670 conserved hypothetical protein U 
 
1.172 
AAEL004809 conserved hypothetical protein U 0.317 0.858 
AAEL004826 conserved hypothetical protein U 
 
-1.156 
AAEL005215 conserved hypothetical protein U 
 
-0.759 
AAEL005620 conserved hypothetical protein U 
 
1.81 
AAEL005755 hypothetical protein U -0.25 1.331 
AAEL006792 conserved hypothetical protein U 
 
-0.865 
AAEL006848 conserved hypothetical protein U -0.606 -0.876 
AAEL006863 hypothetical protein U 
 
3.042 
AAEL006971 conserved hypothetical protein U 
 
0.876 
AAEL007259 conserved hypothetical protein U -0.382 -0.914 
AAEL007342 conserved hypothetical protein U 
 
-0.814 
AAEL007847 conserved hypothetical protein U 
 
1.119 
AAEL008025 conserved hypothetical protein U 0.214 1.749 
AAEL008039 conserved hypothetical protein U 
 
-1.212 
AAEL008100 conserved hypothetical protein U 
 
-0.992 




Gene ID Description Functional group VgDome VgHop 
AAEL008286 conserved hypothetical protein U 
 
-1.18 
AAEL008365 conserved hypothetical protein U 0.262 -1.158 
AAEL008485 conserved hypothetical protein U 
 
-1.848 
AAEL008771 conserved hypothetical protein U 
 
1.584 
AAEL008802 conserved hypothetical protein U -0.479 0.829 
AAEL009177 conserved hypothetical protein U -0.399 -0.864 
AAEL009487 hypothetical protein U 0.282 0.893 
AAEL009519 hypothetical protein U 
 
-0.785 
AAEL010752 hypothetical protein U 
 
-1.077 
AAEL011010 conserved hypothetical protein U 0.325 1.191 
AAEL011330 conserved hypothetical protein U 
 
-0.807 
AAEL011388 conserved hypothetical protein U -0.136 0.756 
AAEL011456 conserved hypothetical protein U 
 
1.762 
AAEL011532 hypothetical protein U -0.694 -0.827 
AAEL011665 hypothetical protein U 
 
-0.762 
AAEL011884 hypothetical protein U 0.395 -2.065 
AAEL012208 hypothetical protein U -0.332 -1.004 
AAEL012454 conserved hypothetical protein U 0.456 1.13 
AAEL012858 hypothetical protein U 
 
-0.952 
AAEL012860 conserved hypothetical protein U 0.573 0.912 
AAEL012867 conserved hypothetical protein U 0.632 1.242 
AAEL013300 conserved hypothetical protein U 
 
-0.786 
AAEL013484 hypothetical protein U 
 
-0.754 
AAEL013486 hypothetical protein U 
 
-1.061 
AAEL013800 conserved hypothetical protein U -0.652 -0.864 
AAEL014171 conserved hypothetical protein U 
 
-1.184 
AAEL014388 conserved hypothetical protein U 
 
-0.913 
AAEL014511 predicted protein U 
 
-0.883 
AAEL014565 hypothetical protein U 
 
-0.957 
AAEL017034 Hypothetical protein U 
 
-1.584 
AAEL017190 Hypothetical protein U 0.227 -1.305 
AAEL017530 hypothetical protein U 
 
-1.363 
AAEL000019 conserved hypothetical protein U 1.278 
 AAEL001032 conserved hypothetical protein U -0.753 -0.462 
AAEL001323 conserved hypothetical protein U 0.933 
 AAEL001511 conserved hypothetical protein U -0.769 -0.653 
AAEL002889 hypothetical protein U 2.243 
 AAEL004100 hypothetical protein U 1.055 0.384 




Gene ID Description Functional group VgDome VgHop 
AAEL005968 conserved hypothetical protein U 1.69 
 AAEL006131 hypothetical protein U 0.861 0.426 
AAEL006585 predicted protein U -0.898 
 AAEL006629 conserved hypothetical protein U -0.79 
 AAEL006676 conserved hypothetical protein U 0.891 0.455 
AAEL006969 conserved hypothetical protein U 1.265 
 AAEL008182 conserved hypothetical protein U -1.003 -0.717 
AAEL012293 conserved hypothetical protein U 1.193 0.317 
AAEL012859 conserved hypothetical protein U -0.75 0.589 
AAEL013287 
conserved hypothetical protein 
(cystatin-like domain; cysteine-
type endopeptidase inhibitor 
activity) U -1.37 0.33 
AAEL013843 conserved hypothetical protein U 1.543 -0.24 
AAEL015379 conserved hypothetical protein U -0.888 
 AAEL017144 Hypothetical protein U 1.364 
 AAEL000566 conserved hypothetical protein U 0.946 1.748 
AAEL001107 hypothetical protein U -0.837 -0.924 
AAEL002652 hypothetical protein U -1.234 -1.081 
AAEL003482 hypothetical protein U 1.257 1.157 
AAEL005106 conserved hypothetical protein U 1.749 0.958 
AAEL007703 conserved hypothetical protein U 3.215 3.352 
AAEL008492 conserved hypothetical protein U 1.721 1.275 
AAEL008729 hypothetical protein U -0.788 -0.835 
AAEL009201 conserved hypothetical protein U 0.754 1.139 
AAEL011928 conserved hypothetical protein U 1.037 0.87 
AAEL012710 conserved hypothetical protein U 0.905 0.831 
AAEL012862 hypothetical protein U 1.151 2.434 
AAEL013734 hypothetical protein U -1.287 -0.987 
AAEL014068 conserved hypothetical protein U 1.351 0.863 
AAEL014300 hypothetical protein U 0.842 0.868 
AAEL014937 hypothetical protein U -0.945 -1.289 
AAEL017016 Conserved hypothetical protein U 0.828 0.958 
AAEL017455 hypothetical protein U -0.981 1.642 
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